

AUTHOR INDEX

Arthritis & Rheumatism, Volume 43, Numbers 1-12, 2000

A

Abrahams VM, 608
Abramson SB, 4, 2260
Abrams WR, 1624
Acevedo E, 370
ACR Audiovisual Aids
 Subcommittee, 493
Adams JL, 175
Adebajo A, 1809
Aganna E, 2034
Agea E, 236
Aguilera S, 2807
Ahn C, 2464
Aho K, 30
Aicher WK, 599
Aigner T, 151
Aitchison R, 1001
Akahoshi M, 711
Akizuki M, 85
Akkermans LMA, 2583
Alarcón GS, 1185, 1902, 2615
Alarcón-Segovia D, 1790
Albert D, 1841
Alcocer-Varela J, 1790
Alexanderson H, 336
Ali M, 2328
Alldersea J, 859
Allen PJ, 349
Alliende C, 2807
Alnigenis MNY, 2617
Alvarez-Ferreira J, 584
Alves H, 758, 1366
Amengual O, 683, 1655, 2142
Amento E, 250
American College of
 Rheumatology Blue Ribbon
 Committee for Academic
 Pediatric Rheumatology, 239
Amesz E, 1465
Amigo M-C, 708
Amin S, 1189
Amor B, 1356
Amoura I, 76
Amoura Z, 76, 689
Andersen GN, 1085
Andersen V, 1657
Anderson JJ, 22
Anderson M, 698
Anderson P, 1327
Andersson U, 2391
Andrade LEC, 85
Andrade SE, 1881
Andrejevic S, 950
Andreu JL, 2848
Andrew T, 2410
Andreyev A, 1560
Annenkov A, 1698
Antohti S, 2464
Antoniades L, 1450, 2410
Aota K, 1756
Arbiser JL, 2189
Archer CW, 215

Arend WP, 1
Armada-Gil L, 894
Armstrong K, 1841
Arnett FC, 1068, 1421, 2464
Arrol HP, 1257
Arroyo RA, 390
Artlett CM, 1062, 2598
Asanuma Y, 2141
Atamas SP, 237, 2733
Atsumi T, 140, 683, 1655, 1982,
 2142
Aupperle KR, 2531
Authier F-J, 1520
Avery G, 541
Awazu Y, 2513
Azuma M, 1756

B

Bach J-F, 76, 689
Bachmann M, 951
Backhaus M, 775
Bacon PA, 1257
Badger AM, 175
Baeten D, 1233
Baggiolini M, 1734
Baggott JE, 2615
Bakharevski O, 821
Balestrieri G, 140
Ballarè M, 94
Ballou LR, 2687
Balsa A, 758, 1366
Banes AJ, 1571
Bankovich AJ, 2265
Bank RA, 2202
Banks S, 2856
Barbashov SF, 2248
Barchowsky A, 801
Bardare M, 1960
Bardin T, 758
Bardy PG, 2851
Barg EC, 1820
Barland P, 461, 2617
Barnden L, 2823
Barr SG, 1801
Barr W, 2445
Barrera P, 758, 1951
Barrett D, 1443
Barrett JH, 234, 1010, 1496,
 1641, 2771
Barthel HR, 1188
Bartram S, 710
Bassotti G, 236
Battafarano DF, 468, 2045
Battagliotti C, 1190
Baudoin P, 2818
Beaulieu AD, 370, 2339
Becker V, 467
Becker W, 298
Beijnen JH, 1951
Bendele AM, 2648
Benderdour M, 1134
Benito MJ, 311

Benjamin M, 576
Benjamin S, 561
Bennett EM, 1378
Bennett LB, 2041
Bentham G, 414
Berenbaum F, 2189
Berner B, 711
Berthelot J-M, 1356, 1901
Bertolaccini ML, 683, 1511,
 1655, 1982
Bertotto A, 236
Beuge N, 1021
Bezemer PD, 2818
Bianchi ML, 1960
Bienvenu J, 1535
Bijl M, 2793
Bijlsma JWI, 465, 1927
Bilbao L, 1094
Billingham ME, 1226, 2634
Billinghurst RC, 664, 673, 2121
Birdi N, 541, 2402
Birkenhäger JC, 1456
Bistoni F, 2678
Bistoni O, 236
Bitzan P, 164, 2501
Black C, 1633, 1641
Blackwell JM, 1397
Blake S, 175
Blank N, 1994
Bläß S, 2307
Block JA, 988
Blom A, 740, 1951
Bloom BJ, 2606
Bober LA, 2660
Bocchio D, 120
Boeck G, 2550
Boehm JC, 175
Boiardi L, 2472
Boiocchi M, 94
Bolaria RK, 541
Bollen ELEM, 2428
Bolognese J, 370, 978
Bombardier C, 506
Bona CA, 2464
Bonaci-Nikolic B, 950
Boncompagni A, 1960
Bondanza A, 1663
Bonfá E, 1033
Bongrand P, 55
Boomsma MM, 2025
Booth DR, 2034
Boots AMH, 645, 1233
Borba EF, 1033
Borg EJ, 1420
Borman P, 1672
Borzi RM, 1734
Bos E, 1233
Bosma GPT, 48, 2428
Boumpas DT, 1244
Bourdel A, 2843
Bowcock AM, 2041
Brañas F, 1183
Brandi ML, 1960
Brandt J, 1346
Brandt KD, 1192
Bräuer R, 298
Braun J, 720, 1346, 2834
Brayer J, 2297
Brebant M, 1356
Breedveld FC, 129, 155, 270,
 593, 946, 1115, 1465, 1488,
 1710, 1820
Brennan P, 1010
Bresnahan B, 712, 1001, 2619
Breuer GS, 1184
Brinckerhoff CE, 801
Brinson DC, 1307
British Paediatric Rheumatology
 Group, 1496
Britti D, 320
Brock JH, 2073
Brooks D, 834
Brooks P, 4
Brooks WM, 1904
Brousseau P, 2614
Brown MA, 1353
Brucato A, 1049
Bruns A, 2307
Bruyn GAW, 2608
Bucala R, 827
Buckner JH, 939
Bukilica M, 950
Bullough PG, 2423
Bulpitt KJ, 2743
Buma P, 2121
Bungay P, 704
Bunn C, 1633
Burdick MD, 1266
Burger H, 1456
Burkhardt H, 298
Burmester G-R, 775, 2307
Bustillo J, 1054
Butler JJ, 1580
Buyon J, 550
Byrd VM, 2152
Bywaters EGL, 2011

C

Cacoub P, 55, 76
Cahue S, 568, 1874
Caidahl K, 1085
Caillat-Vigneron N, 1520
Caldwell JR, 978
Caliandro D, 140
Calin A, 1353
Caliz AR, 683
Cáliz R, 735
Cambridge G, 608
Campagne BN, 531
Campos H, 689
Canhão H, 470
Cannon GW, 978, 1278
Canoso J, 708
Capraro D, 1994

AUTHOR INDEX

Arthritis & Rheumatism, Volume 43, Numbers 1-12, 2000

A

Abrahams VM, 608
Abramson SB, 4, 2260
Abrams WR, 1624
Acevedo E, 370
ACR Audiovisual Aids
 Subcommittee, 493
Adams JL, 175
Adebajo A, 1809
Aganna E, 2034
Agea E, 236
Aguilera S, 2807
Ahn C, 2464
Aho K, 30
Aicher WK, 599
Aigner T, 151
Aitchison R, 1001
Akahoshi M, 711
Akizuki M, 85
Akkermans LMA, 2583
Alarcón GS, 1185, 1902, 2615
Alarcón-Segovia D, 1790
Albert D, 1841
Alcocer-Varela J, 1790
Alexanderson H, 336
Ali M, 2328
Alldersea J, 859
Allen PJ, 349
Alliende C, 2807
Alnigenis MNY, 2617
Alvarez-Ferreira J, 584
Alves H, 758, 1366
Amengual O, 683, 1655, 2142
Amento E, 250
American College of
 Rheumatology Blue Ribbon
 Committee for Academic
 Pediatric Rheumatology, 239
Amesz E, 1465
Amigo M-C, 708
Amin S, 1189
Amor B, 1356
Amoura I, 76
Amoura Z, 76, 689
Andersen GN, 1085
Andersen V, 1657
Anderson JJ, 22
Anderson M, 698
Anderson P, 1327
Andersson U, 2391
Andrade LEC, 85
Andrade SE, 1881
Andrejevic S, 950
Andreu JL, 2848
Andrew T, 2410
Andreyev A, 1560
Annenkov A, 1698
Antohti S, 2464
Antoniades L, 1450, 2410
Aota K, 1756
Arbiser JL, 2189
Archer CW, 215

Arend WP, 1
Armada-Gil L, 894
Armstrong K, 1841
Arnett FC, 1068, 1421, 2464
Arrol HP, 1257
Arroyo RA, 390
Artlett CM, 1062, 2598
Asanuma Y, 2141
Atamas SP, 237, 2733
Atsumi T, 140, 683, 1655, 1982,
 2142
Aupperle KR, 2531
Authier F-J, 1520
Avery G, 541
Awazu Y, 2513
Azuma M, 1756

B

Bach J-F, 76, 689
Bachmann M, 951
Backhaus M, 775
Bacon PA, 1257
Badger AM, 175
Baeten D, 1233
Baggiolini M, 1734
Baggott JE, 2615
Bakharevski O, 821
Balestrieri G, 140
Ballarè M, 94
Ballou LR, 2687
Balsa A, 758, 1366
Banes AJ, 1571
Bankovich AJ, 2265
Bank RA, 2202
Banks S, 2856
Barbashov SF, 2248
Barchowsky A, 801
Bardare M, 1960
Bardin T, 758
Bardy PG, 2851
Barg EC, 1820
Barland P, 461, 2617
Barnden L, 2823
Barr SG, 1801
Barr W, 2445
Barrera P, 758, 1951
Barrett D, 1443
Barrett JH, 234, 1010, 1496,
 1641, 2771
Barthel HR, 1188
Bartram S, 710
Bassotti G, 236
Battafarano DF, 468, 2045
Battagliotti C, 1190
Baudoin P, 2818
Beaulieu AD, 370, 2339
Becker V, 467
Becker W, 298
Beijnen JH, 1951
Bendele AM, 2648
Benderdour M, 1134
Benito MJ, 311

Benjamin M, 576
Benjamin S, 561
Bennett EM, 1378
Bennett LB, 2041
Bentham G, 414
Berenbaum F, 2189
Berner B, 711
Berthelot J-M, 1356, 1901
Bertolaccini ML, 683, 1511,
 1655, 1982
Bertotto A, 236
Beuge N, 1021
Bezemer PD, 2818
Bianchi ML, 1960
Bienvenu J, 1535
Bijl M, 2793
Bijlsma JWI, 465, 1927
Bilbao L, 1094
Billingham ME, 1226, 2634
Billinghurst RC, 664, 673, 2121
Birdi N, 541, 2402
Birkenhäger JC, 1456
Bistoni F, 2678
Bistoni O, 236
Bitzan P, 164, 2501
Black C, 1633, 1641
Blackwell JM, 1397
Blake S, 175
Blank N, 1994
Bläß S, 2307
Block JA, 988
Blom A, 740, 1951
Bloom BJ, 2606
Bober LA, 2660
Bocchio D, 120
Boeck G, 2550
Boehm JC, 175
Boiardi L, 2472
Boiocchi M, 94
Bolaria RK, 541
Bollen ELEM, 2428
Bolognese J, 370, 978
Bombardier C, 506
Bona CA, 2464
Bonaci-Nikolic B, 950
Boncompagni A, 1960
Bondanza A, 1663
Bonfá E, 1033
Bongrand P, 55
Boomsma MM, 2025
Booth DR, 2034
Boots AMH, 645, 1233
Borba EF, 1033
Borg EJ, 1420
Borman P, 1672
Borzi RM, 1734
Bos E, 1233
Bosma GPT, 48, 2428
Boumpas DT, 1244
Bourdel A, 2843
Bowcock AM, 2041
Brañas F, 1183

Brandi ML, 1960
Brandt J, 1346
Brandt KD, 1192
Bräuer R, 298
Braun J, 720, 1346, 2834
Brayer J, 2297
Brebant M, 1356
Breedveld FC, 129, 155, 270,
 593, 946, 1115, 1465, 1488,
 1710, 1820
Brennan P, 1010
Bresnahan B, 712, 1001, 2619
Breuer GS, 1184
Brinckerhoff CE, 801
Brinson DC, 1307
British Paediatric Rheumatology
 Group, 1496
Britti D, 320
Brock JH, 2073
Brooks D, 834
Brooks P, 4
Brooks WM, 1904
Brousseau P, 2614
Brown MA, 1353
Brucato A, 1049
Bruns A, 2307
Bruyn GAW, 2608
Bucala R, 827
Buckner JH, 939
Bukilica M, 950
Bullough PG, 2423
Bulpitt KJ, 2743
Buma P, 2121
Bungay P, 704
Bunn C, 1633
Burdick MD, 1266
Burger H, 1456
Burkhardt H, 298
Burmester G-R, 775, 2307
Bustillo J, 1054
Butler JJ, 1580
Buyon J, 550
Byrd VM, 2152
Bywaters EGL, 2011

C

Cacoub P, 55, 76
Cahue S, 568, 1874
Caidahl K, 1085
Caillat-Vigneron N, 1520
Caldwell JR, 978
Caliandro D, 140
Calin A, 1353
Caliz AR, 683
Cáliz R, 735
Cambridge G, 608
Campagne BN, 531
Campos H, 689
Canhão H, 470
Cannon GW, 978, 1278
Canoso J, 708
Caprarú D, 1994

Caputi AP, 320
 Carbone LD, 1054
 Cardiel MH, 1790
 Carlson CS, 2081, 2110
 Carruthers DM, 1257
 Carson DA, 2571
 Carter JD, 1418
 Caruso A, 140
 Casali P, 140
 Casciola-Rosen L, 881
 Casey B, 1165
 Caspi D, 103
 Catella-Lawson F, 1891
 Catelli L, 1049
 Cattini L, 1734
 Cebrián M, 184
 Cernieux J, 1881
 Cervera R, 2349, 2801
 Cervini C, 969
 Cha S, 2297
 Chabre H, 76
 Chan D, 1679
 Chan SY, 1679
 Chandler P, 349
 Chang P-L, 1597
 Chapman K, 1423
 Chapman PT, 38
 Charles PJ, 2383
 Charron D, 758
 Chatham WW, 1185
 Chen D-F, 2378
 Chen EH, 2368
 Chen J, 664, 673
 Chen S-L, 289
 Chérin P, 1520
 Chernajovsky Y, 1698
 Cheung NT, 2614
 Chew J, 2823
 Chicpeportiche R, 270
 Chisholm R, 698
 Chlipala ES, 2648
 Choi HK, 226, 405, 2316, 2488
 Chopin M, 2056
 Choquette D, 1410, 2339
 Choy B, 2189
 Christiansen L, 400
 Christner PJ, 2598
 Chrousos GP, 872
 Chung JB, 1841
 Cicchillitti L, 2219
 Cicuttini F, 2543
 Cid MC, 184, 235, 1428
 Cimaz R, 1049, 1960
 Clancy RM, 2260
 Claret E, 1790
 Clark AG, 1426
 Clarke AE, 1410
 Claudepierre P, 1356
 Clauw DJ, 243
 Clayton D, 1397
 Clements PJ, 2445
 Cloutier J-M, 2100
 Coakley G, 834
 Cobby M, 1001
 Cobelens PM, 2583, 2694
 Coelen R, 365
 Coenen-de Roo CJJ, 645

Coggon D, 995, 1443
 Cohen P, 2339
 Cohen Tervaert JW, 2025
 Coindreau J, 708
 Colamussi P, 1903
 Colbert RA, 2290
 Coleman PJ, 1175
 Coles EC, 1473
 Collier D, 2445
 Coll-Vinent B, 184, 235, 1428
 Colombo G, 120
 Conaghan PG, 713, 950, 1809, 2762
 Cone JD, 2493
 Conejero L, 1366
 Connor JR, 1290
 Contreras MA, 2848
 Conway RF, 2598
 Coon CI, 801
 Cooper C, 995, 1443
 Cornélis F, 758
 Cornely D, 1346
 Corona F, 1960
 Corrigan VM, 1606
 Corr M, 2571
 Corthay A, 844
 Cosgrove DM III, 901
 Costa Dias F, 470
 Costantino G, 320
 Coste J, 1858
 Costello P, 712
 Cox LA, 1062
 Craig ML, 2265
 Crawford B, 506
 Crofford LJ, 4, 1891
 Croft JD Jr, 1429
 Croft P, 1443
 Cronstein BN, 656
 Crowl RM, 2634
 Csepregi A, 232
 Cuadrado MJ, 1511
 Cuppari GG, 1661
 Curiel DT, 1094
 Curran S, 712
 Currie MG, 1290
 Cuzzocrea S, 320

D

Dababneh A, 1749
 Dabadghao P, 1397
 Dahlberg L, 664, 673
 D'Alfonso S, 120
 Dallman MJ, 1688
 Danao-Camara T, 2853
 Daniels B, 978
 Danning CL, 930, 1244
 Das A, 2359
 David C, 946
 David J, 1849
 Davies KA, 349
 Davies LW, 2091
 Davis JC Jr., 930
 Dawes PT, 859, 2614
 Dayer JM, 270
 de Almeida G, 758
 de Bandt M, 2056
 deBenedictis FM, 236

De Carolis S, 140
 Dedhiya S, 1478
 Degraeve EJ, 2011
 de Groot K, 1021, 2854
 de Jong BAW, 155, 1831, 2428
 De Jong J, 2383
 De Keyser F, 1233
 Dekker-Saeyns AJ, 2818
 Dekkers JC, 465
 de Koster BM, 1488
 de la Concha EG, 758, 1366
 de la Red G, 2801
 de la Sierra A, 235, 1428
 Delmas PD, 953
 Del Papa N, 140
 Delpech M, 1535
 Delrieu O, 1422
 Delyle LG, 2843
 Deng G-M, 356, 2283
 Denisova A, 1397
 Dennis GJ, 943
 De Re V, 94
 Derksen RHW, 2793
 Dermis-Labous E, 1356
 Desai A, 656
 De Vita S, 94
 Devogelaer J-P, 281
 de Vries N, 947
 de Vries RRP, 129, 946
 Devulder B, 889
 de Waal Malefijt MC, 1951
 Diacerein Study Group, 2339
 Diamond JS, 1191
 Di Battista JA, 1134
 Dieppe PA, 995
 Diggs S, 2297
 Dijkmans BAC, 2818
 Dijkstra bloem HM, 2793
 Ding W-Z, 2378
 Dion E, 1535
 DiRocco M, 1542
 Di Simone N, 140
 Disla E, 1661
 Distler O, 2005
 Dixon JA, 2609
 Dobers J, 1616
 Dodd I, 2590
 Dodé C, 1535
 Dolzani P, 2472
 Dong X, 85
 Donn RP, 1496
 Doré CJ, 1849
 Dorrier C, 506
 Dougados M, 1356
 Doughan AM, 988
 Dowling B, 1423
 Dracheva S, 1278
 Draenert R, 709
 Dragomir AD, 1426
 Dreja H, 1698
 Drosos AA, 471
 Drossaers-Bakker KW, 1465
 Drucker Y, 1187
 D'Souza AL, 1315
 Du Bois RM, 1633
 Duché A, 1356
 Dugan EM, 1866

Dunlop DD, 568
 Duparc F, 2843
 Dupuis M, 2100
 Durand J-M, 55
 Duvic C, 2633
 Dykens J, 1560

E

Edwards CK III, 2648
 Edwards JCW, 608
 Eger W, 206, 1165
 Egido J, 311
 Ehrlich E, 978
 Ehrlich GE, 1430
 Eisenberg R, 1430
 Eivazova ER, 429
 Ekman P, 1527
 Elahi S, 1874
 Elbim C, 2056
 Elewaut D, 1233
 Elferink JGR, 1488
 Elliott MJ, 38
 Emery P, 713, 865, 950, 1809, 1820, 2328, 2762
 Emilie D, 1790
 Endo H, 2455
 Endres JL, 329
 Engelman L, 1874
 Engström M, 2391
 Enzenauer RJ, 468
 Erkan D, 472, 714
 Escalante A, 390
 Escolar G, 2349
 Esdaile JM, 1410
 Esparza J, 184
 Espinosa G, 2349
 Espinosa-Morales R, 390
 Eto S, 2513
 European Consortium on Rheumatoid Arthritis Families, 758
 Evans CH, 1156, 2563
 Evans JM, 1041
 Eymard B, 1520
 Eyre DR, 939

F

Facchini A, 1734, 2472
 Falaschi F, 1405
 Falch JA, 522, 2776
 Falchuk KR, 2609
 Falcini F, 1960
 Farina A, 969
 Farnarier C, 55
 Farnell J, 1820
 Fassbender HG, 151
 Fazzini F, 1663
 Feldman BM, 541, 2402
 Feldmann M, 38, 638, 1688, 2383
 Felson DT, 22, 1189, 1874
 Fernandes C, 704
 Fernandes JC, 1290
 Fernández ML, 584
 Fernández-Arquero M, 1366
 Fernihough JK, 1226

Ferraccioli G, 94
 Fertig N, 444
 Fiddler M, 1010
 Fieschi C, 1535
 Fife MS, 1673
 Fijnheer R, 2793
 Filippucci E, 969
 Finger DR, 707
 Finkel TH, 1430
 FIN-RACo Trial Group, 2397
 Firestein GS, 469, 2531
 Fischer P, 2722
 Fisher SA, 1673
 Fishman AD, 461
 FitzGerald O, 712
 Flatø B, 1504
 Flavahan NA, 1886
 Flavahan S, 1886
 Fleer A, 2583
 Foley P, 1633
 Fonollosa V, 894
 Fonseca JE, 470
 Font C, 184, 235, 1428
 Font J, 2349, 2801
 Førre Ø, 1504
 Fortin PR, 1410
 Foster H, 710
 Fox DA, 329
 Francis R, 710
 François RJ, 2011
 Frank ME, 2064
 Franz JK, 599, 1597
 Fraser PA, 2378
 Frazier J, 2648
 Freire C, 2349
 Freseman T, 1543
 Frigge ML, 2785
 Fritz P, 758
 Frizziero L, 2472
 Frosch M, 628
 Fryer AA, 859
 Fujii K, 2513
 Fujii T, 85
 Fulbright JW, 1041
 Funa K, 2046
 Funke A, 1655
 Furst DE, 2005

G

Gaeddicke G, 2722
 Gaidarova S, 1624, 2219
 Galanaud P, 1790
 Galbiati E, 1960
 Ganga A, 1941
 García S, 735
 García-Carrasco M, 2801
 García-Padilla C, 1790
 García-Porrúa C, 584, 1183, 1427, 1749, 2855
 Gardin JF, 2110
 Gardner DL, 2011
 Gardner JC, 1378
 Gardner PP, 2328
 Garner P, 953
 Garot N, 1976
 Garred P, 515, 1657
 Gasparotto D, 94

Gatel A, 55
 Gaudry M, 2056
 Gay RE, 599, 1226, 1597, 1710, 1719, 2523, 2531, 2634
 Gay S, 599, 1226, 1597, 1710, 1719, 2523, 2531, 2634
 Gayet A, 109
 Geenen R, 465
 Geiger ME, 1327
 Geiler T, 1994
 Genant HK, 1001
 Gensler TJ, 1327
 Georgescu HI, 1156
 Gérard HC, 1543
 Gerhardt C, 1387
 Geyer A, 711
 Gherardi RK, 1520
 Ghivizzani SC, 1156, 2563
 Ghosh P, 812
 Giannini EH, 2335, 2611
 Gibbon WW, 2762
 Gillespie MT, 821
 Gillum JD, 2041
 Girgis RE, 699
 Giuntini D, 1960
 Glass DN, 2335, 2611
 Gleich G, 1897
 Glisson M, 2543
 Glorioso JC, 2563
 Godaert GLR, 465
 Goddard G, 461
 Godeau P, 1535
 Gohr CM, 1729
 Goicovich E, 2807
 Goker B, 988
 Golder W, 1346
 Goldring MB, 1916, 2189
 Goldring SR, 250, 2143
 González C, 2848
 Gonzalez J, 1346
 González M-J, 2807
 González S, 485
 González-Gay MA, 584, 1183, 1427, 1749, 2855
 Gooi H-C, 2328
 Goorha S, 2687
 Gordon C, 1410
 Gordon TP, 1647, 2851
 Gore LR, 400
 Gorman JD, 930
 Goronzy JJ, 1041
 Gougerot-Pocidallo M-A, 2056
 Gough A, 1809
 Goulet JR, 1410
 Govoni M, 1903
 Gowen M, 175
 Grace MJ, 2660
 Graff E, 103
 Graff RD, 1571
 Grainger J, 1849
 Granfors K, 1527
 Grangeot-Keros L, 1790
 Grassi W, 969
 Grateau G, 1535
 Grau JM, 184, 235, 1428
 Graudal HK, 515
 Graudal NA, 515

Gravallese EM, 250, 2143
 Green DR, 469
 Green MJ, 865, 1809, 2762
 Greer MR, 1244
 Grégoire R, 55
 Greidinger EL, 881
 Griffiths B, 1809, 2328
 Griffiths MM, 1278
 Grimbergen JM, 1710
 Griswold DE, 175
 Grodzicky T, 1410
 Gromnica-Ihle E, 1543
 Groot K, 2855
 Gross WL, 226, 1021, 1654, 2854
 Grossin M, 2056
 Grötsch P, 1994
 Groupe D'Etudes et de Recherche sur les Maladies Musculaires Acquises et Dysimmunitaires, 1520
 Groupe Français D'Etude Génétique Des Spondylarthropathies, 1356
 Group for Research on Auto-Immune Disorders, 1422
 Gruber J, 2550
 Gründer W, 298
 Grünke M, 1994
 Grupp C, 467
 Gruschwitz MS, 2550
 Guballa N, 550, 2380
 Gugnani MK, 699
 Guillaume S, 1858
 Guillen C, 2073
 Guis S, 1356
 Gulcher J, 2785
 Gumanovskaya ML, 195
 Gupta S, 1891
 Gurwitz JH, 1881

H

Habot B, 103
 Hachulla E, 889
 Hagiwara M, 1516
 Hahn BH, 715
 Hahn P, 1897
 Haibel H, 1346
 Haines GK III, 1122, 1266
 Hajeer AH, 1749
 Halberg P, 1657
 Hall A, 1849
 Hallgrimsdóttir IB, 2785
 Halloran MM, 1266
 Halse JI, 522, 2776
 Halsey J, 698
 Hamada H, 1106
 Hamilton AD, 1624
 Hamlin G, 365
 Handley CJ, 2211
 Hann A, 215
 Hannonen P, 386, 2397
 Hansson A-S, 844
 Harada A, 452
 Harada K, 1756
 Haraoui B, 2339
 Harashima S, 135
 Hards DK, 821
 Harlé J-R, 55
 Harms E, 628
 Harmsen W, 2583
 Harrold LR, 1881
 Hashiramoto A, 1278
 Haskard DO, 1779, 2855
 Hassager C, 710
 Hassell AB, 859
 Hassett AL, 2493
 Hasson N, 1849
 Hasty KA, 195
 Hasunuma T, 1106
 Hatano Y, 1419
 Hatron P-Y, 889
 Hattori N, 65
 Haugeberg G, 522, 2776
 Haugen M, 1504
 Hausdorf G, 2307
 Hawkey C, 370
 Hawkins PN, 2034
 Hayashi Y, 1756
 Haywood MEK, 349
 Hazenberg MP, 593, 2160
 Hazes JMW, 155, 1465, 1902
 Heatley S, 2851
 Hebbbar M, 889
 Hefferton D, 1662
 Heijnen CJ, 2583, 2694
 Heinegård D, 1425, 1742
 Héjias M, 232
 Heller M, 1021
 Helliwell PS, 865, 1809
 Helsen MMA, 645
 Henderson CJ, 531, 710
 Henry LA, 1729
 Henry PA, 2733
 Herborn G, 14, 1903
 Herbst H, 151
 Hermans J, 2025
 Hernández P, 311
 Hernández T, 1183
 Hernández-Rodríguez J, 184, 1428
 Hernanz-Schulman M, 2359
 Herrero-Beaumont G, 311
 Herrick AL, 698, 704
 Herson S, 1520
 Hertzman PA, 243
 Herzog V, 2417
 Hess EV, 243
 Hetthen J, 865
 Hicks J, 1866
 Hiepe F, 2307
 Hieronymus T, 1994
 Hiesberger H, 420
 Higuchi M, 135
 Hilal G, 2297
 Hillyer P, 1779
 Hirose J, 2703
 Hirose K, 2455
 Hitchon C, 1244
 Hitman GA, 2034
 Hochberg MC, 400
 Hoet RMA, 2132
 Hofbauer R, 164
 Hoffman GS, 901, 1191

Hoffman RW, 881
 Hoffman SJ, 175
 Hofman A, 1456
 Hogarth MB, 349
 Höhlig K, 2417
 Hollander AP, 2121
 Holmdahl R, 844
 Holthuysen AEM, 740
 Holt P, 978
 Hong DK, 2368
 Horányi M, 232
 Horiuchi T, 135
 Hornez L, 889
 Horton WE, 1580
 Hosaka S, 1122
 Hosoya T, 925
 Houssiau FA, 1976
 Hoyle E, 1353
 Huang N, 1094
 Huang Q, 1456
 Huber AM, 541
 Hübscher S, 2513
 Hudson AP, 1543
 Hughes GRV, 140, 683, 1511,
 1655, 2142
 Huhtala H, 1371
 Huisman LGM, 1710
 Huizinga TWJ, 48, 129, 1710,
 2428
 Hulsman HMJ, 1927
 Hummel KM, 599, 1597
 Humphreys-Beher MG, 2297
 Hunder GG, 1041
 Hurley F, 495
 Hurwitz EL, 2445
 Huston G, 1809
 Hutchinson P, 2537
 Hynes K, 2543

I

Ichikawa K, 1982
 Ieko M, 1982
 Ihn H, 2240
 Izuka H, 259
 Ikeda E, 812
 Ikeda K, 452
 Ikeda Y, 65
 Illic MZ, 2211
 Illei GG, 1244
 Imai S, 1218
 Infante R, 1661
 Ingelmo M, 2349, 2801
 Ingvarsson T, 2785
 Ioannou Y, 1431
 Ionescu M, 664, 673
 Ip WK, 1679
 Iqbal M, 834
 Irjala K, 1016
 Isaacs JD, 1809, 2328, 2762
 Isenberg DA, 1410, 1431, 2617
 Ishii M, 2612
 Ishii T, 1616
 Itakura M, 925
 Iwamoto I, 2455
 Iwata S, 1616

J

Jackson JV, 2660
 Jacobs JWG, 1927
 Jacobsen S, 1657
 Jaffurs D, 2563
 Jakez-Ocampo J, 1790
 Janicka I, 2169
 Jansen MD, 2793
 Jarrett R, 2823
 Jeffery DR, 1190
 Jelaska A, 2230
 Jeronimo ALC, 689
 Jessop JD, 1473
 Jiang Y, 1001
 Jiménez SA, 1062, 1624, 2219,
 2598, 2801
 Jin W, 2064
 Job-Deslandre C, 1858
 Joe B, 1278
 Johannet C, 689
 John S, 1673, 2771
 Johnson K, 1145, 1560
 Johnstone B, 1156
 Jolicœur F-C, 1134
 Jones G, 2543
 Jones PW, 859
 Jönsson H, 2785
 Jönsson H Jr., 2785
 Joo Y-S, 329
 Joosten LAB, 645, 1300
 Jordan JM, 1426
 Joseph L, 917, 1410
 Jovanovic DV, 1134, 1290
 Juji T, 259
 Jung A, 1560
 Jurik AG, 515

K

Kabir FN, 85
 Kaburaki J, 65, 1074
 Kalden JR, 238, 298, 1994
 Kallenberg CGM, 2025, 2793
 Kamatani N, 852, 925, 2615
 Kameoka Y, 1419
 Kamimoto T, 1516
 Kane D, 712
 Kang AH, 1054, 2687
 Kanik KS, 1418
 Kankainen A, 386
 Kapadia R, 175
 Kapiotis S, 164
 Kaplan MJ, 1891
 Kaplanski G, 55
 Kaprio J, 30
 Kartogiannis V, 821
 Kasama T, 1419
 Kasukawa R, 1900, 2578
 Katada Y, 2612
 Katayama R, 2178
 Kato T, 1106, 2712
 Katschke KJ Jr., 1122
 Katsumata K, 1655
 Kauppi MJ, 2397
 Kautiainen H, 2397
 Kavelaars A, 2583, 2694
 Kawahito Y, 1278
 Kawai S, 469, 2141
 Kawakami Y, 65, 1074
 Kazkaz H, 1187
 Kazzam E, 1085
 Keijsers V, 129
 Kellingray S, 995, 1443
 Kellner H, 709
 Kephart GM, 1897
 Kern P, 238
 Khamashta MA, 140, 683, 1511,
 1655, 2142
 Kiener HP, 164
 Kimball AB, 1866
 Kim HK, 557
 Kim JM, 473
 Kim S, 1122
 Kim SJ, 1327
 Kimura T, 617, 2178
 Kinder JM, 2368
 Kingsbury DJ, 2290
 Kingsley GH, 720
 Kinne RW, 298, 329, 775, 945
 Kinsella TR, 2368
 Kirchner T, 151
 Kirveskari J, 1527
 Kishimoto T, 1591
 Kitasato H, 469
 Klareskog L, 2391
 Klein CL, 1597
 Klein MJ, 2668
 Klickstein LB, 2248
 Klippel JH, 930
 Knight C, 1633
 Knudson CB, 206, 1165
 Knudson W, 206, 1165, 1315
 Kobata T, 1106
 Kobayashi H, 2578
 Kobayashi T, 1106
 Koch AE, 1122, 1266
 Koenig S, 908
 Koike T, 683, 1218, 1982
 Kojima T, 135
 Koldingsnes W, 2481
 Komata T, 753
 Kong SX, 917
 Kontny E, 2169
 Kontinen YT, 275
 Korganow A-S, 908
 Korn JH, 2230
 Koshihara Y, 259
 Kosinski M, 1478
 Koskenvuo M, 30
 Koutourov S, 76, 689
 Kowalczewski J, 2169
 Kozłowski K, 1387
 Kraan MC, 270, 1488, 1820
 Kraetsch H-G, 775
 Kramer PPG, 2694
 Kratz A-K, 336
 Krause D, 14, 1903
 Kraus VB, 1426
 Krausz T, 1779
 Krieg AM, 468
 Kriegsmann J, 1597
 Kronborg G, 1657
 Kroot E-JJA, 1831
 Kuchen S, 1226, 2634

Kucich U, 1624
 Kuettner KE, 206, 1165
 Kuis W, 628
 Kunkel SL, 1266
 Kuntz KM, 1967, 2316
 Künzler P, 2523, 2634
 Kurasawa K, 2455
 Kurokawa M, 2712
 Kurowska M, 2169
 Kuwana M, 65, 1074
 Kvammen J, 1504
 Kvien TK, 522, 2776
 Kwan APL, 215
 Kwiatak R, 2823
 Kyburz D, 2571

L

Labaye J, 2633
 Labouret N, 908
 La Brooy J, 365
 Laforêt P, 1520
 Lahita RG, 1768
 Laine L, 370
 Laman JD, 2160
 Lambert NC, 2005
 Lamprecht P, 226, 1654
 Lanchbury JS, 834, 1673
 Landis RC, 1779
 Lane NE, 378, 400
 Lane SE, 414
 Lang BA, 541, 2402
 Langford CA, 1836
 Lascau-Coman V, 1290
 Latza U, 1021
 Lau CS, 1679
 Lau YL, 1679
 Lauret P, 109
 Lauster R, 2834
 Lauwers G, 1897
 Lauwers BR, 1976
 Laval SH, 1353
 LaValley MP, 1189
 La Ville AE, 894
 Lawton AR, 2359
 Laxer RM, 2402
 Lazarowski ER, 1571
 Le M, 1729
 Leach MW, 2660
 Leandro MJ, 470
 LeBlanc CMA, 541
 Le Blévec G, 1356
 Lechevallier J, 109
 Lechman ER, 2563
 Ledosseur P, 109
 Lee GM, 1571
 Lee JC, 175
 Leech M, 827
 Leflunomide Rheumatoid
 Arthritis Investigators Group,
 495, 506
 Leirisalo-Repo M, 1371, 2397
 Leleu J-P, 1186
 Le Loët X, 109, 2843
 LeLorier J, 917
 Lemelle I, 1849
 Lenz M-E, 281
 Lepage V, 758

Lepore L, 1960
 Lerch H, 2722
 Lester S, 2851
 Leung H, 495
 Levallois H, 908
 Levarht EWN, 1115
 Levesque MC, 1190
 Levick JR, 1175
 Lewis B, 1881
 Lewis CM, 1673
 Lewis NM, 1655
 Lewis PA, 1473
 Leyton C, 2807
 Li T-F, 275
 Libbey CA, 1184
 Lien G, 1504
 Liljestrom M, 275
 Lima J, 894
 Limburg PC, 2025, 2793
 Lin P, 400
 Linton SM, 2590
 Liotta-Davis MR, 2368
 Lipsky PE, 4
 Lisner R, 151
 Litton T, 944
 Liu D, 1094
 Liu D-W, 289
 Liu Q, 1886
 Liu R, 1145
 Liu Z-Q, 2283
 Llorca J, 1427
 Llorente L, 1790
 Lockshin MD, 440, 550, 2380
 Loeser RF, 1552, 2081, 2110
 Loew-Friedrich I, 495
 Lohmander LS, 2785
 Lohse A, 2139
 Lopes-Vaz A, 758
 López-Armada MJ, 311
 López-Larrea C, 485
 López-Lazaro L, 584
 López-Soto A, 235, 1428
 Lorenz H-M, 1994
 Lorenzo P, 1742
 Lotsikas AJ, 872
 Lotz M, 1307
 Lou C, 568
 Loughlin J, 1423
 Love LA, 243
 Lovell DJ, 531, 710
 Lu L-Y, 2378
 Lubart E, 103
 Lubberts E, 645, 1300
 Lubrano E, 865
 Lucas M, 444
 Lucio M, 584
 Luisetto G, 1960
 Lundberg I, 336
 Luta G, 1426
 Luukkainen R, 2397
 Luzina I, 2733
 Lydyard PM, 608
 Lympany P, 1633

M

Macchioni P, 2472
 MacDonald KPA, 791

Macfarlane GJ, 561
 MacGregor AJ, 30, 1450, 1641, 2410
 Mackman N, 1145
 MacNeil I, 541
 Madsen HO, 515, 1657
 Maenaut K, 758
 Maetzel A, 506
 Magder LS, 1801
 Magid SK, 714
 Maibaum MA, 349
 Maillefert JF, 468
 Maini RN, 38, 638, 2046, 2383, 2391
 Maldonado-Cocco J, 370
 Malleson P, 541
 Malloy MA, 707
 Mandelin J, 275
 Manfra D, 2660
 Manfredi AA, 1663
 Manger B, 238
 Manicourt D-H, 281
 Manner P, 673
 Manning C, 250
 Manning PT, 1290
 Månsson B, 1425
 Manzi S, 1410
 Maragall S, 2349
 Maranhão RC, 1033
 Marchesoni A, 865
 Marcinkiewicz J, 2169
 Marin V, 55
 Marinova-Mutafchieva L, 638, 2046
 Markham AF, 2328
 Marks RM, 329
 Maroudas A, 2202
 Marshall D, 1779
 Martel-Pelletier J, 1134, 1290, 2100
 Martín J, 735
 Martignoni A, 1405
 Martin M, 1809
 Martin RW, 2445
 Martin T, 908
 Martin TJ, 821
 Martínez A, 1366
 Martínez B, 2807
 Martínez L, 775
 Martínez M, 758
 Martínez-Borra J, 485
 Martínez-Lavín M, 708
 Martini A, 1405
 Maruo A, 2513
 Masliński W, 2169
 Mason LJ, 638
 Mason RM, 1175
 Masuda I, 2703
 Masuko-Hongo K, 2712
 Matarán L, 735
 Mateo-Cambón L, 1183
 Matson M, 1450, 2410
 Matsubara L, 1218
 Matsuda Y, 852
 Matsui T, 2712
 Matsumoto S, 2513
 Matsuno H, 617, 2178
 Matsushita M, 753
 Matsuta K, 753
 Matsuura E, 1982
 Matthey DL, 859, 1749, 2614
 Mauri C, 638
 Mayes MD, 243, 2445
 Mazzetti I, 1734
 Mazzon E, 320
 Mazzullo G, 320
 McAlindon TE, 995
 McBeth J, 561
 McCabe D, 1001
 McCall-Vining S, 1278
 McCloskey R, 38
 McCrary CT, 656
 McCune WJ, 1891
 McDermott MF, 2034
 McDonagh KT, 1891
 McDonald MC, 320
 McDonnell JM, 429
 McElhenny JL, 2265
 McGonagle D, 713, 950, 1809, 2762
 McInnes IB, 1244, 2073
 McKown KM, 1054
 McLaren M, 1443
 McLean B, 978
 Mear JP, 2290
 Medsger TA Jr., 243, 444, 2437, 2445
 Mejjad O, 109
 Meliconi R, 2472
 Melief M-J, 2160
 Mendes A, 758
 Mendez EP, 2368
 Mendonça LLF, 1511
 Mengshol JA, 801
 Mercie P, 1186
 Merkel PA, 226, 405, 2488
 Meroni PL, 140, 1049
 Merrill JT, 1768
 Metz C, 827
 Meulenbelt I, 1424
 Meyer CM, 493
 Meyer P, 298
 Meyers M, 2138
 Mi Z, 2563
 Miceli-Richard C, 1356
 Michot C, 109, 2843
 Miettinen A, 1371
 Migliavacca D, 1405
 Migliorini P, 758
 Mikuls TR, 464
 Miles S, 1809
 Miller EN, 1397
 Miller FW, 243, 1866
 Miller GG, 2152
 Miller ML, 85
 Millward-Sadler SJ, 2091
 Miltenburg AMM, 645, 1233
 Mima T, 1591
 Mimori T, 65, 1074
 Minami Y, 2513
 Mincheva-Nilsson L, 1085
 Mindrescu C, 2668
 Mineau F, 1134, 2100
 Mitrofanoff P, 109

Miyake T, 1591
 Miyata M, 1900, 2578
 Miyauchi A, 452
 Miyazaki T, 259
 Mizrahi J, 2202
 Mizugaki Y, 1218
 Mok CC, 1679
 Moldovan F, 2100
 Molina C, 2807
 Momigliano-Richiardi P, 120
 Momy J-A, 541
 Montague BMN, 2328
 Monteagudo J, 2349
 Montellà N, 894
 Montesinos MC, 656
 Monteverde A, 94
 Moore AD, 1410
 Moos V, 2417
 Morand EF, 827, 2537
 Moreland L, 2445
 Moreno MJ, 1190
 Morgan AW, 2328
 Morgan BP, 2590
 Morgan SL, 1185, 2615
 Miorham SG, 2687
 Morimoto C, 1616
 Moritani M, 925
 Morley BJ, 349
 Morris S, 561
 Morris SM, 881
 Morrow JD, 1891
 Mortensen E, 370
 Mosci P, 2678
 Mota-Filipe H, 320
 Motegi K, 1756
 Motta C, 894
 Möttönen T, 1016, 2397
 Mougin C, 2139
 Mountz JD, 1094
 Moutsopoulos HM, 471, 1187
 Mukhopadhyay S, 978
 Mulero J, 2848
 Müller B, 2417
 Müller GA, 467
 Muller S, 420
 Müller-Ladner U, 599, 1597, 2005
 Mullighan CG, 2851
 Munakata Y, 1616
 Muñoz-Rodríguez FJ, 2349
 Munteanu SE, 2211
 Murata N, 1591
 Muro Y, 1516
 Murphy A, 1560
 Murphy FT, 2045
 Musset L, 76
 Mustafa Z, 1423
 Mustila A, 1371
 Myers LK, 2687
 Myerscough A, 2771

N

Nagasawa K, 135
 Nahir MA, 2339
 Naito A, 250
 Najundawamy SN, 2378
 Nakagawa T, 259

Nakajima H, 852
Nakamura H, 812
Nakamura K, 259
Nakashima H, 711
Nakazawa F, 617, 2178
Narula SK, 2660
Naschitz JE, 2618
Nash GB, 1337

Nawata Y, 2455
Nawrath M, 599
Nédélec G, 2633
Neidhart M, 1719, 2531, 2634
Nelson AE, 2359
Nelson F, 673
Nelson JL, 234, 2005
Nemesánszky E, 232
Neugebauer KM, 1768
Neva MH, 2397
Nevitt MC, 400
Nguyen KH-T, 2297
Nicholson-Weller A, 2248
Niedobitek G, 151
Nielsen S, 710
Niermann KJ, 2359
Nieto A, 735
Nieuwenhuis EES, 2583, 2694
Niho Y, 135
Nikolic MM, 950
Niles JL, 226, 405, 2488
Nishida Y, 206, 1165, 1315
Nishioka K, 1106, 1591, 2464, 2712
Nishizaka H, 135
Nissilä M, 2397
Niyibizi C, 1156
Noll RB, 1387
Nölle B, 1021
Nomi M, 2513
Nomura S, 1591
Nori M, 1616
Nossent H, 2481
Nuki G, 2091

O

Oates JC, 1891
O'Connell M, 1145
O'Connor P, 2762
Oda H, 259
O'Dell J, 464
O'Driscoll BR, 698, 704
Ogunkolade BW, 2034
Ohashi J, 753
Ohshima S, 1591
Ohuchi E, 812
Okada Y, 812
Okamoto K, 1106
Okamoto R, 469
Okuzumi H, 452
Older SA, 390, 468
Ollier WER, 1641, 1673, 1749, 2771
Olsen NJ, 2359
Oost W, 2025, 2793
Ordinas A, 2349
Orefici G, 2678
Osada R, 2178
Osei A, 2722

Østergaard M, 949
Osterhaus JT, 1478
Ostrov BE, 2856
O'Sullivan B, 791
O'Sullivan MM, 1473
Otsuka T, 711
Overzet K, 1327
Özoran K, 1672

P

Pachman LM, 85, 2368
Paget SA, 472
Paimela L, 1371
Palacios I, 311
Paleolog E, 38
Palombo-Kinne E, 298
Pan C, 250
Pan G, 2488
Pan R-Y, 289
Panayi GS, 471, 834, 1606, 1673
Pantelidis P, 1633
Panzeri P, 1049
Pap T, 599, 1226, 1710, 2523, 2531
Papanicolaou DA, 872
Papo T, 1535
Park G, 2743
Park JH, 2359
Park YS, 557
Pascual M, 735
Pascual V, 2041
Pascual Salcedo D, 758, 1366
Pasquali J-L, 908
Passo M, 1387
Patarroyo M, 336
Patel A, 765
Patella SJ, 2493
Paulus HE, 2743
Pease C, 1809, 2762
Pêcheux C, 1535
Peck AB, 2297
Pedersen FK, 710
Peen E, 1897
Peeva E, 461
Pelletier J-P, 1134, 1290, 2100, 2339
Peng H-J, 289
Penrod J, 1410
Perälä M, 1742
Perani G, 1405
Perdriger A, 1356
Pereira da Silva JA, 470
Pérez P, 2807
Peters AM, 38
Petersen J, 1657
Petersson A-S, 1085
Petri M, 1410, 1801
Petrov PK, 1597
Pettit AR, 791
Peyrat J-P, 889
Pianon M, 1660
Picard F, 1535
Picco P, 1960
Pickering MC, 2855
Piero SG, 1660
Pierre YS, 1410
Pierson C, 699

Piette J-C, 55, 76, 689, 1422, 1535
Pile K, 2823
Pileri S, 94
Pillemer SR, 872
Pilo CM, 2064
Pincus T, 243, 1659
Pinto R, 2807
Pisetsky DS, 2381
Pistorio A, 1405
Pivetta B, 94
Pla M, 2056
Plant MJ, 1473
Poilvache P, 281
Poitras JM, 943
Pollard KM, 1327
Pols HAP, 1456
Ponchel F, 2328
Poole AR, 664, 673, 2121
Poór G, 232
Poormoghim H, 444
Posadas I, 656
Post WJ, 1488
Postlethwaite AE, 1054, 2687
Potter K, 1580
Prahald S, 2335, 2611
Prieur AM, 1849, 1858
Prince CW, 1597
Pritzker K, 1145
Proudman SM, 1809
Prud'homme JF, 758
Pujol RM, 584
Puliti M, 2678
Pulpeiro JR, 1183
Pulsatelli L, 2472
Punzi L, 1660

Q

Quan H, 370
Quattrocchi E, 1688
Quax PHA, 1710
Quinn JMW, 821

R

Raats JMH, 2132
Radbruch A, 2834
Radford DJ, 1337
Radic MZ, 2132
Radstake TRDJ, 758
Ragnarsson JJ, 2785
Rahman P, 1662
Rahme E, 917
Rajamäki A, 1016
Ralphs JR, 576
Ramires JAF, 1033
Ramos B, 2743
Ramos-Casals M, 2801
Rampi M, 120
Ramselaar CG, 1420
Rantapää-Dahlqvist S, 1085
Rappaport B, 2618
Raschi E, 140
Ratliiff NB, 901
Rau R, 14, 1903
Ravelli A, 1405
Raymond Y, 951
Reddig J, 1346
Redlich K, 164, 2501
Reece RJ, 1809, 1820
Reed AM, 85
Reed JI, 1881
Reese VR, 1278
Reeves WH, 85
Register TC, 2081
Reife RA, 939
Reiner A, 664, 673
Reinhold-Keller E, 1021, 1654, 2854
Remmers EF, 1278
Renaud J-C, 1976
Rennie T, 2045
Renzone E, 1633
Reparon-Schuijt CC, 1115
Resende C, 470
Rethage J, 2634
Reuss-Borst MA, 467, 711
Reuter M, 1654
Reveille JD, 1421, 2464
Reverter JC, 2349
Rich WJ, 2648
Richardson C, 1809
Richaud-Patin Y, 1790
Richmond RS, 2081
Rider LG, 1866
Rieman DJ, 175
Rigby AS, 30
Rijnders AWM, 1233
Rincón I, 390
Rischmueller M, 1647, 2851
Robb D, 1662
Robbins JR, 2189
Robbins PD, 1156, 2563
Roberts B, 365
Robinson N, 765
Rodenburg RJT, 1941
Rodríguez-Ledo Y, 1427
Rofecoxib Osteoarthritis Endoscopy Multinational Study Group, 370
Rofecoxib Phase III Protocol 035 Study Group, 978
Rojas-Triana A, 2660
Rojkovich B, 232
Rojo-Leyva F, 901
Romas E, 821
Romero FI, 1655, 2142
Romero N, 1520
Romo R, 2807
Ronday HK, 1710
Rood MJ, 48, 129, 2428
Rooney N, 151
Roopenian DC, 2290
Rose SJ, 349
Rosen A, 881
Rosenbloom J, 1624
Rosenbloom JC, 1624
Rosenburg R, 1820
Rosenthal AK, 1729
Rosloniec EF, 2687
Rosner IA, 2339, 2618
Roth J, 628
Roth MB, 1768
Rousseau JC, 953

Rovere P, 1663
Rowe C, 2823
Rozenbaum M, 2618
Rozier BCD, 1115
Rubin RL, 420
Rudert H, 1021
Rudwaleit M, 2417
Rufai A, 576
Rugarli C, 1663
Rumba I, 1397
Russano A, 236
Russell E, 944
Russo R, 1190
Ryan LM, 2703
Ryan MH, 2335, 2611
Ryan PFJ, 821
Ryder C, 1849
Ryder NM, 2359

S

Säämänen A-M, 1742
Sabbadini MG, 1663
Saeki Y, 1591
Said LA, 109
Said-Nahal R, 1356
Saito K, 2513
Saitta B, 1624, 2219
Saka M, 1900
Sakane T, 945
Salminen H, 1742
Salter DM, 2091
Salvarani C, 2472
Sammaritano LR, 440, 550, 2380
Sampey AV, 2537
Sanchez ML, 1655
Sánchez-Pernaute O, 311
Sánchez-Tapias JM, 2801
Sandorfi N, 1624
Sanjeevi CB, 1397
Sano H, 2455
Santavirta S, 275
Saraux A, 1356, 1901
Sarkar S, 329
Sartori M, 1405
Sasajima T, 2578
Sasakawa H, 2712
Sasaki T, 2464
Sato M, 1756
Sato Y, 2578
Satoh M, 85
Sattler B, 467
Savage COS, 1337
Sawabe T, 135
Saxne T, 1425, 1742
Schacht E, 1188
Schedel J, 1597
Scheepers RHM, 2793
Schellekens GA, 155
Schenk Y, 1927
Scherrer J, 2648
Schett G, 420, 2501
Schleusser B, 14, 1903
Schmaier AH, 1891
Schmid BJ, 2501
Schmidt D, 234
Schmidt WA, 1543
Schneider R, 2402

Schnitzer TJ, 988
Scholze S, 775
Schouls LM, 593
Schreuder GMT, 129
Schrijver IA, 593, 2160
Schumacher HR, 930, 1430
Schwartz JS, 1841
Schwartzman S, 440, 550, 2380
Scorza-Smeraldi R, 120
Scott D, 1175
Scott DGI, 414
Seal SN, 2132
Seaman WE, 1204
Sebt SM, 1624
Seçkin U, 1672
Seeger JD, 2316
Segal R, 103
Seibold JR, 2445
Seidenberg B, 978
Sekine T, 2712
Semsei I, 951
Sendo W, 852
Senécal J-L, 951, 1410
Sennello G, 2648
Sepp N, 2550
Sestini P, 1633
Seyer JM, 1054
Sgonc R, 2550
Shah CJ, 1673
Shahane A, 370
Shanker G, 1552, 2081, 2110
Sharma L, 568, 1874
Sharp JT, 495, 1378
Shaw M, 85
Shear ES, 2335, 2611
Shelton BJ, 2110
Shepard JS, 1278
Shibue T, 753
Shigeyama Y, 599, 1226, 2523
Shikhman AR, 1307
Shimizu M, 1591
Shinkai H, 2455
Shiota M, 753
Shlopov BV, 195, 2687
Shtauvere A, 1397
Shuler FD, 1156
Sibbitt RR, 1904
Sibbitt WL Jr., 1904
Sibilia J, 468, 1356
Sickinger S, 945
Sieper J, 720, 1346, 2417, 2834
Sierra RI, 531
Sigal LH, 2380, 2493
Silman AJ, 30, 234, 561, 1010, 1641
Silver RM, 243
Silverman ED, 2402
Silvestri T, 2472
Simeón P, 894
Simmen BR, 1226, 2523
Simms RW, 1189
Simon LS, 4, 1192
Simon T, 370
Simpson E, 349
Singer NG, 329
Situnayake RD, 2328
Slagboom PE, 1424

Slingsby JH, 349
Slobodin G, 2618
Slot MC, 2488
Sluiter WJ, 2793
Smeenk RJT, 2383
Smeets TJM, 270, 1820
Smith A, 1423
Smith GN Jr., 1192
Smith P, 1156
Smith R, 2590
Smolen JS, 164, 420, 2501
Smythe CDW, 1779
Sneller MC, 1836, 2853
Snieder H, 30
Snow S, 995
Soden M, 365
Sokka T, 386
Sokoll K, 865
Solá R, 894
Solans R, 894
Solau-Gervais E, 1606
Soley A, 908
Solomon DH, 1967
Song KS, 557
Song X-Y, 2064
Sonntag WE, 2110
Sorg C, 628
Sorsa T, 275
Sørkaar D, 1504
Soudry M, 2202
Southwood TR, 1496, 1849
Spaepen M, 758
Specker BL, 531
Spector TD, 1450, 2410
Speckenbrink ABJ, 2073
Spence RJ, 1886
Spencer RGS, 1580
Spiegel LR, 2402
Spinuzzi F, 236
Spyropoulou M, 758
Staines NA, 429
Steen VD, 2437, 2445
Steenbakkers PGA, 1233
Stefánsson SE, 2785
Stegeman CA, 2025
Stein CM, 1659
Stein L, 85
Steiner C-W, 2501
Steiner G, 164, 420, 2501
Stephens D, 2402
Stiller KJ, 298
Stivers DN, 1068, 1421
Stoop R, 2121
Storm G, 1951
Stramba-Badiale M, 1049
Strand V, 495, 506, 2615
Strange RC, 859
Straus W, 1881
Stravopoulos C, 758
Strey A, 628
Strieter RM, 1266
Stroup GB, 175
Stuart B, 995
Stuhlmüller B, 775
Suemura M, 1591
Summers RM, 1866
Sunderkötter C, 628

Suominen P, 1016
Susol E, 1641
Sutcliffe N, 1410
Sutton BJ, 429
Suzuki K, 1419
Suzuki N, 945
Sveigaard A, 515, 1657
Swift BA, 175
Swinkels H, 1831
Swoboda B, 151
Sykes B, 1423
Szatmári I, 1188
Szczepańska K, 2169
Szegedi G, 951
Szekanecz Z, 1266
Szondy Z, 1188

T

Tak PP, 270, 593, 1488, 1820, 2160, 2619
Takabayashi K, 2455
Takács I, 951
Takada K, 1218
Takagi Y, 452
Takayanagi H, 259
Takeda T, 1218
Takeuchi F, 925
Takizawa M, 812
Talar-Williams C, 1836
Tamaki K, 2240
Tamatani T, 1756
Tan FK, 1068, 1421, 2464
Tanaka C, 2712
Tanaka H, 1616
Tanaka M, 852
Tanaka S, 259
Tanaka Y, 2513
Taniguchi A, 852
Tanzer M, 673
Tarkowski A, 356, 2276, 2283
Tarp U, 515
Tas SW, 2248
Tassies D, 2349
Taurog JD, 2290
Tavernier C, 468
Taylor J, 1387
Taylor PC, 38, 638, 2046, 2391
Taylor RP, 2265
Tchetverikov I, 593
Tedman R, 2823
Teixeira da Costa JC, 470
TeKoppele JM, 1710, 2202
Tenenbaum S, 1190
Terato K, 939
Terkeltaub R, 1145, 1560
Tew SR, 215
Thiel A, 2834
Thiemermann C, 320
Thieu T-H, 2152
Thomas B, 2188
Thomas E, 1496
Thomas JW, 2152
Thomas R, 791
Thomine J-M, 109
Thompson A, 506
Thompson EM, 349
Thompson SD, 2335, 2611

Thomson BM, 215
 Thomson W, 1496, 1749
 Thonar EJ-MA, 281, 1315
 Thorbecke GJ, 2668
 Thriene W, 1346
 Tidmore W, 1886
 Tijssen H, 947
 Tincani A, 140
 Tissi L, 2678
 Todesco S, 1660
 Tohidast-Akrad M, 164, 2501
 Tojo T, 1074
 Tokuhira M, 1122
 Tokunaga K, 753
 Tomita Y, 1516
 Tondur PR, 2608
 Tong KK, 1679
 Tonks S, 2378
 Torpy DJ, 872
 Tournier-Lasserre E, 1422
 Toussiot E, 1239
 Trejo O, 2801
 Trevisani VFM, 85
 Trination Study Group, 1410
 Tsao BP, 1421
 Tsao Y-P, 289
 Tsay A, 250
 Tsuchiya N, 753
 Tsukamoto H, 135
 Tsutsumi A, 1982
 Twell P, 506
 Turner M, 1866
 Tyagi S, 2248
 Tylee TS, 2005

U

Uda H, 2612
 Uguccioni M, 1734
 Uhlig T, 522, 2776
 Uitterlinden AG, 1456
 Uko G, 2378
 Ulfgren A-K, 2391
 Umeshita-Sasai M, 1591
 Ungethüm U, 775
 Urbán L, 951
 Urbano-Márquez A, 184, 235, 1428
 Uttenreuther-Fischer MM, 2722
 Utz PJ, 1327

V

Vaith P, 234
 Valdimarsson H, 1657
 Valent P, 164
 Valeriano-Marcet J, 1418
 van Albada-Kuipers GA, 1927
 van Bloois L, 1951
 van Buchem MA, 48, 2428
 van de Loo FAJ, 1300
 van de Putte LBA, 4, 740, 758, 947, 1831, 1941, 1951
 van de Winkel JGJ, 740, 2793
 van den Berg WB, 645, 740, 1300, 1951, 2121
 van den Bersselaar LAM, 1300
 van den Hoogen FHJ, 155, 1831
 Vanderheide R, 699

van der Heijde DMFM, 1809, 1927
 van der Heijden IM, 593
 van der Horst-Bruinsma IE, 2818
 van der Kraan PM, 2121
 van der Laan WH, 1710, 2531
 van der Leij MJ, 2025
 van der Linden MW, 129
 van der Zee R, 2694
 van Doornen LJP, 465
 van Duijn CM, 1424, 1456
 Van Eden W, 2694
 Van Egeren A, 281
 van Elderen C, 947
 van Esch WJE, 1115
 van Gestel AM, 1658
 van Kooten C, 1115
 van Krugten MV, 129
 van Leeuwen JPTM, 1456
 van Leeuwen MA, 1831
 van Lent PLEM, 740, 1941, 1951
 Vannatta K, 1387
 van Riel PLCM, 947, 1658, 1831
 van Rijswijk MH, 1831
 van Rooijen N, 1951
 van 't Hof M, 1831
 van Venrooij WJ, 155, 1327, 1831, 1902, 1941
 van Vuuren AJ, 740
 van Wart HE, 673, 664
 Varga J, 243
 Varsani H, 765
 Vasey FB, 1418
 Vasudevan H, 365
 Vasudevan S, 365
 Vaughan D, 2073
 Vázquez-Caruncho M, 584
 Veale D, 865, 1809, 1820, 2762
 Verbruggen G, 1233
 Verdringh M, 2276, 2283
 Verduyn W, 129
 Verheijden GFM, 1233
 Verheijen JH, 1710, 2531
 Verhoef J, 2583
 Verhoeven AC, 22
 Versendaal J, 270
 Verweij CL, 129, 1115
 Veys EM, 1233
 Viana Queiroz M, 470
 Vignon E, 468
 Víkingsson A, 1657
 Vilardell M, 894
 Vilček J, 2668
 Vilim V, 1426
 Vinagre CGC, 1033
 Vincenti MP, 801
 Vinje O, 1504
 Virtanen I, 275
 Visser H, 155
 Visser MR, 2583
 Vittecoq O, 109, 2843
 Vogl T, 628
 Volin MV, 1122, 1266
 Von Hunolstein C, 2678
 Vos K, 946

Voulgarelis M, 1187
 Vuorio E, 1742

W

Wadler S, 461
 Wagner AD, 1543
 Wahl SM, 2064
 Wakefield RJ, 1809, 2762
 Wakui M, 753
 Walchshofer S, 164
 Waldenström A, 1085
 Walker AM, 405
 Walmsley MJ, 638
 Walport MJ, 349
 Wang J, 85, 1278
 Ward FE, 1190
 Ware JE Jr., 1478
 Waterman SA, 1647
 Watson DJ, 917
 Watt I, 1001
 Watts RA, 414
 Webb E, 175
 Webb G, 673
 Weber A-J, 2056
 Weber J-C, 908
 Wedderburn LR, 765
 Weeks M, 1881
 Weinberg JB, 1190
 Weinblatt ME, 2609
 Weinreich S, 2818
 Weisman MH, 473, 977, 2445
 Weissbach CA, 2488
 Wells A, 1633
 Wells G, 22, 506
 Welsh K, 1633, 1641
 Wendling D, 2139
 Wener MH, 1768
 Wergin S, 944
 Westendorp RGJ, 129
 Western Consortium of Practicing Rheumatologists, 2743
 Westhovens R, 758
 Weyand CM, 1041
 White B, 237, 2445, 2733
 Wick G, 2550
 Wiener CM, 1886
 Wigler I, 2339
 Wigley FM, 1886, 2445, 2733
 Wijdenes J, 1790
 Wilbrink B, 593
 Wilder RL, 872, 1278
 Williams AL, 1473
 Williams AS, 2590
 Williams BD, 2590
 Williams EN, 400
 Williams RC Jr., 1897
 Williams RO, 638
 Wilson H, 1641
 Wiltink EHH, 1420
 Winchester R, 712
 Winkler S, 1994
 Wise CA, 2041
 Wisniewski H-G, 2668
 Witte DP, 2290
 Wolfe F, 378, 2753

Wong WK, 2445, 2743
 Woo P, 765, 1849
 Woods JM, 1266
 Wordsworth BP, 1353
 Worthington J, 1641, 1673, 2771
 Wright MO, 2091
 Wu J-J, 939
 Wu P, 2834
 Wu S, 1886
 Wu W, 664
 Wulfraat NM, 628

X

Xiao X, 289
 Xu Q, 2501

Y

Yagnik DR, 1779
 Yamada Y, 452
 Yamagami T, 2612
 Yamagoe S, 1419
 Yamaguchi N, 1591
 Yamamoto A, 259
 Yamamoto AM, 689
 Yamamoto K, 2712
 Yamamoto T, 2423
 Yamanaka H, 812, 852, 925, 2615
 Yamashita T, 1756
 Yang P, 1094
 Yap JS, 656
 Yaron M, 103, 2339
 Yasunari U, 2297
 Yazici Y, 472, 714
 Yengi L, 859
 Yeshurun D, 2618
 Yonezawa T, 617
 Yood RA, 1881
 Yoshida M, 1900
 Yoshizaki K, 1591
 Yoshizawa S, 135
 Young A, 2617
 Young SP, 1257
 Yudoh K, 617, 2178
 Yurovsky VV, 2733

Z

Zak M, 710
 Zanelli E, 129, 946
 Zapor M, 2045
 Zeher M, 951
 Zeidler H, 1543
 Zeihen M, 944
 Zeng L, 2064
 Zenz P, 2501
 Zhang H-G, 1094
 Zhang X, 1094
 Zhao SZ, 378, 1478
 Zhou T, 1094
 Zhou X, 1068
 Zimmermann VS, 1663
 Zonana-Nacach A, 1801
 Zuckerman E, 2618
 Zukor D, 673
 Zulian F, 1960
 Zvaifler NJ, 469, 2046
 Zwiderman AH, 48, 1465

SUBJECT INDEX

Arthritis & Rheumatism, Volume 43, Numbers 1-12, 2000

A

- AA amyloidosis, autosomal dominant periodic fever associated with in Indian family, 2034, 2379
- Abortion, trophoblast gonadotropin secretion and invasiveness affected by antiphospholipid antibodies, 140
- Acetabular dysplasia, increased risk of incident hip OA in elderly white women with, 400
- Acetaminophen
comparison with NSAIDs, occurrence and cost of GI side effects, 917
comparison with NSAIDs, survey of OA, RA, and fibromyalgia patients, 378
- Acetylcholine, adhesion in endothelial cells prevented by, 2260
- Achilles tendon, bony spurs, mechanism of formation, 576
- Acidic fibroblast growth factor, in synoviocytes, 2152
- Acinar cells, suppression of MMP-9 in SS by adding inhibitor of NF- κ B α cDNA, 1756
- Acne vulgaris, chronic destructive oligoarthritis associated with, 2843
- Activator protein 1, IL-8 expression stimulated by monosodium urate monohydrate and calcium pyrophosphate crystals in monocytic cells, 1145
- Adenosine receptor antagonists, reversal of antiinflammatory effects of MTX by theophylline and caffeine, 656
- Adenovirus-mediated gene transfer
of CTLA-4Ig fusion protein in suppression of autoimmune arthritis, 1688
of insulin-like growth factor 1 in proteoglycan synthesis in rabbit joints, 2563
- Adhesion molecules
acetylcholine prevention of ICAM-1-induced focal adhesion complex assembly, 2260
correlation between increased NO production and markers of endothelial activation in SSc, 1085
primary APS and SLE-related APS, increased sVCAM concentrations and severity of thrombosis in, 55
- Adjuvant-induced arthritis
disease-modifying activity of SB 242235, 175
inflammatory cytokines and chemokines in, 1266
mycobacterial Hsp65 treatment of, 2694
oral antibiotics as novel arthritis therapy, 2583
regulation of macrophage migration inhibitory factor in, 827
reversal of antiinflammatory effects of MTX by theophylline and caffeine in, 656
temporal expression of inflammatory cytokines and chemokines in, 1266
- African American populations, SLE susceptibility in populations of sub-Saharan African ancestry, 2378
- Afro-Caribbean populations, SLE susceptibility in populations of sub-Saharan African ancestry, 2378
- Aggrecan
catabolism of in articular cartilage inhibited by calcium pentosan polysulfate, 2211
hyaluronan metabolism stimulation by IL-1 α in articular cartilage, 1315
osteogenic protein 1 and cell-associated matrix assembly by normal articular chondrocytes, 206
TNF α and oncostatin M, correlation with degradation markers of collagen and aggrecan in RA but not OA, 281
- Aging. *See also* Elderly patients
CILP/NTPPH and ePPI with, 2703
osteoblastic cells, cellular activity and replicative capacity of in patients with RA compared with OA, 2178
- Aging. *See also* Elderly patients (*cont'd*)
reducing chondrocyte response to insulin-like growth factor 1 in, 2110
- Albumin, intraarticular hyaluronan-albumin interaction in attenuation of fluid drainage from joints, 1174
- Alendronate, for OA in diffuse connective tissue diseases in children, 1960
- Allopurinol, antibody-positive vasculitis prevalence in patients with high antimyeloperoxidase antibody levels, 405 α_2 -adrenergic constriction, in diffuse SSc, 1886
- Alternative medicine, for SLE, 1410
- American College of Rheumatology (ACR)
20% criteria for improvement in RA, 2743
1999 Slide Competition winners, 493
Arthritis & Rheumatism in 2000, 1
pediatric rheumatology in the US, strategic planning, 239
presidential address, 715
recommendations for management of hip and knee OA, 1905
- Anemia, serum transferrin receptor and transferrin receptor ferritin index to detect in RA, 1016
- Angiogenesis
endostatin in patients with SSc, 889
leukocyte-endothelial cell interactions in GCA, 184
Angiogenesis inhibitor, arthritis suppression and protection from bone destruction with TNP-470/AGM-1470 in RA, 2056
- Animal models. *See specific animals*
- Ankylosing spondylitis (AS)
infliximab treatment of, 1346
risk of development among first-born children, 2818
sacroiliitis in, 2011
X-chromosome and susceptibility to, 1353
- Ankylosis, T cells and enthesal ossification in DBA/1 mice, 844
- Annexin I, surface binding sites and fibroblast-like synoviocytes, 2537
- Anterior crural neuralgia, as presenting manifestation of lymphocele, 1183
- Antibiotics. *See also names of specific antibiotics*
oral antibiotics as novel arthritis therapy, 2583
- Antibodies/autoantibodies. *See names of specific antibodies*
- Antibody-dependent cell toxicity, endothelial cell apoptosis in SSc induced via CD95, 2550
- Antibody-positive vasculitis (APV), prevalence in patients with high antimyeloperoxidase antibody levels, 405
- Anti-CD4, for early collagen-induced arthritis, 638
- Anti-CD40 ligand, prevention and treatment of arthritis in K/BxN mouse model, 2571
- Anti-CD44, inhibition of cartilage destruction, in vitro, 1719
- Antichromatin antibodies, LE cell phenomenon, 420
- Anti-cyclic citrullinated peptide antibody, prognostic value in patients with recent-onset RA, 1831
- Anti-DEK antibodies, autoantibodies to DEK oncoprotein in JRA, 85
- Anti-DNA IgG autoantibodies, in SLE, 2132
- Anti-DNA topoisomerase I autoantibody, response in SSc, 1074, 2733
- Anti-double-stranded DNA autoantibodies
clearance of, 2265
TNF α blockers and induction of, 2381, 2383
- Antidymple antibodies, in connective tissue diseases, 1516
- Anti-endothelial cell antibodies (AECA)
in normal and lupus pregnancy, 1511
in SSc, 2550
- Anti-fibrillin 1 antibodies, in SSc, 2464
- Antigen-based heteropolymers, clearance of anti-double-stranded DNA antibodies, 2265

- Antigen-induced arthritis
 cyclosporin A to prevent histologic damage without inducing fibrosis, 311
 FCR γ chain in, 740
 membrane-targeted complement regulator in rat models, 2590
 microscopic cartilage alterations in rat knee joint, 298
- Anti-histone H1 testing, antichromatin antibody specificity in lupus erythematosus cell-positive and -negative sera, 420
- Antiidiotypic antibodies, cross-reactivity with DNA in SLE, 429
- Anti-interleukin-1, inhibition of cartilage destruction by, 1719
- Anti-interleukin-10, in SLE, 1790
- Antikeratin antibody, in RA diagnosis, 2617
- Anti-lamin B1 antibodies, in SLE, 950, 951
- Antileukoproteinase scintigraphy, microscopic cartilage alterations in rat knee joint with antigen-induced arthritis, 298
- Antimuscarinic acetylcholine receptor antibody, secretory dysfunction in NOD mice and, 2297
- Antimyceloperoxidase antibodies, antibody-positive vasculitis prevalence and, 405
- Antineutrophil cytoplasmic antibodies (ANCA)
 as early RA marker, 1371
 neutrophil adhesion and, 1337
 predicting relapses in Wegener's granulomatosis by, 2025
 seroconversion induced by minocycline, sulfasalazine, or penicillamine, 2488
 subacute bacterial endocarditis with, 226
- Antinucleosome antibodies, IgG3 subclass as markers of renal pathogenicity in SLE, 76
- Antiperinuclear factor, in RA diagnosis, 2617
- Antiphosphatidylserine/prothrombin autoantibodies, associated with HLA class II genes, 683
- Antiphospholipid antibodies
 T cell autoreactivity to β_2 -glycoprotein I in, 65
 trophoblast gonadotropin secretion and invasiveness affected by, 140
- Antiphospholipid syndrome (APS)
 angiotensin-converting enzyme gene polymorphism and risk of arterial thrombosis in, 1655
 association of autoantibodies against phosphatidylserine-prothrombin complex with, 1982
 ovulation induction and in vitro fertilization in, 550
 polymorphism of plasminogen activator inhibitor gene and thrombosis in, 2349
 primary APS and SLE-related APS, increased sVCAM concentrations and severity of thrombosis in, 55
 T cell autoreactivity to β_2 -glycoprotein I in, 65
 trophoblast gonadotropin secretion and invasiveness affected by, 140
 validation of Sapporo criteria for, 440
- Anti-protein S antibodies, prevalence in patients with SLE, 557
- Anti-proteinase 3 antibodies, subacute bacterial endocarditis with, 226
- Anti-RNP antibodies, pathogenic significance in rheumatic diseases, 689
- Anti-Ro antibodies, QT interval prolongation in asymptomatic anti-SSA/Ro-positive infants without congenital heart block, 1049
- Anti-SSA/Ro antibodies
 association with "shrinking lung," 2612
 QT interval prolongation in asymptomatic anti-SSA/Ro-positive infants without congenital heart block, 1049
- Anti-TNF α
 autoimmune rheumatic manifestations induced by, 1436
 for early collagen-induced arthritis, 638
 induction of anti-DNA autoantibodies, 2381, 2383
 infliximab treatment of AS, 1346
 infliximab treatment of RA, 2383, 2391
 prevention and treatment of arthritis in K/BxN mouse model, 2571
 retards synovial TNF synthesis, 2391
- Anti-TNF α /anti-CD4, for early collagen-induced arthritis, 638
- Anti-topoisomerase I antibody, response to in SSc, 1074, 2733
- Apolipoprotein(a), deposition in atherosclerotic coronary arteries of patient with SLE, 2141, 2142
- Apoptosis
 in autoimmunity origin and maintenance, 1663
 chlorpromazine-induced in activated human lymphoblasts, 1994
 of endothelial cells in SSc induced by antibody-dependent cell toxicity via CD95, 2550
 experimental wounding of articular cartilage and, 215
 Fas-mediated, differential regulation of in rheumatoid synoviocytes by TNF α and basic growth factor, 1106
 fibroblast selection and activation in SSc, 2230
 inhibition of inducible nitric oxide synthase and OA progression, 1290
 sentrin at sites of synovial invasion in RA, 599
 small nucleolar RNP scleroderma autoantigens associate with phosphorylated serine/arginine splicing factors during, 1327
 sulfasalazine inhibits TNF α expression in macrophages by inducing, 1941
 TNF α -induced, of human synovial fibroblasts, 1094
- Arend, William P., in appreciation of, 1191
- Arterial stenosis, inflammatory, 238
- Arterial thrombosis, in patients with APS, 1655
- Arthritis & Rheumatism*
 in 2000, 1
 in appreciation of William P. Arend, 1191
 available online, 592, 851
 introducing David S. Pisetsky as new editor, 1429
- Arthritis Care and Research*, available online, 592, 851
- Aspirin, mini-dose effect on renal function and uric acid handling in elderly, 103
- Assisted reproduction treatment, in patients with SLE and APS, 550, 2380
- Atherosclerosis, in juvenile-onset SLE, nephrotic-range proteinuria as risk factor for, 1405
- Atlantoaxial subluxations, combination DMARD therapy vs. single-DMARD therapy for RA, 2397
- Autoantibodies. *See names of specific autoantibodies*
- Autoantigens
 quantitative radioligand assays in connective tissue diseases, 689
 in reactive arthritis, 728
 small nucleolar RNP scleroderma autoantigens associate with phosphorylated serine/arginine splicing factors during apoptosis, 1327
 SR proteins as autoantigens in patients with SLE, 1768
- Autoimmune arthritis, adenovirus-mediated gene transfer of CTLA-4Ig fusion protein in suppression of, 1688
- Autoimmune encephalomyelitis, oral antibiotics as novel therapy for, 2583
- Autosomal dominant periodic fever
 associated with AA amyloidosis in Indian family, 2034, 2379
 TNFRI C30S mutation linked to autosomal dominant recurrent fever with localized myositis, 1535

B

- B cells
 non-neoplastic oligoclonal expansion of in type II mixed cryoglobulinemia, 94
 nucleosomes as autoantigens in SLE, 2307
 regulation of synovial B cell survival in RA by VCAM-1, 1115
 salivary gland lymphomas in SSc patients from rheumatoid factor B cells, 908
- Bacteria, reactive arthritis-associated, 720
- Bacterial DNA
 arthritis features induced by CpG motifs in, 356
 in joints of RA patients, 593, 1061

- Bacterial DNA (*cont'd*)
 macrophages and induction of arthritis triggered by bacterial DNA containing CpG motifs, 2283
- Bacterial peptidoglycans
 in joints of RA patients, 593, 1061
 in synovial tissue of RA patients, 2160
- Basic fibroblast growth factor, differential regulation of Fas-mediated apoptosis of rheumatoid synoviocytes by, 1106
- Beau's lines, after severe gold dermatitis, 1420
- Behçet's syndrome, false-positive results on Mantoux test, 2855
- β_2 -glycoproteins
 T cell autoreactivity to β_2 -glycoprotein I in APS, 65
 trophoblast gonadotropin secretion and invasiveness affected by antiphospholipid antibodies and through adhered β_2 -glycoprotein, 140
- Birth order, risk of developing AS among first-born children, 2818
- Bisphosphonates, alendronate for OA in diffuse connective tissue diseases in children, 1960
- Bladder cancer, in Wegener's granulomatosis patients treated with cyclophosphamide, 2853, 2854
- Body mass index (BMI), knee OA and, 568
- Bone
 arthritis suppression and protection from bone destruction with TNP-470/AGM-1470 in RA, 2056
 bone erosion in RA, cellular mechanisms and role of cytokines in, 2143
 collagen-induced arthritis, expression of osteoclast differentiation factor at bone erosion sites, 821
 markers of, molecular basis and clinical use of, 953
 MRI bone erosions and bone lesions in early RA, 949, 950
 normal peak bone mass at lumbar spine and forearm in young adults with juvenile arthritis in remission, 1504
 osteoblastic cells, cellular activity and replicative capacity of in patients with RA compared with OA, 2178
 osteoclastogenesis from synoviocytes in RA, 259, 2523
 sonography for detection of bone erosion in RA, 2762
 synovial tissue as source of osteoclast differentiation factor in RA, 250
- Bone marrow, anti-DNA IgG autoantibodies and SLE, 2132
- Bone mineral density
 in female RA patients, 522
 hip OA and, 1450
 in juvenile arthritis patients, 710, 1504
 in male RA patients, 2776
 in non-corticosteroid-treated postpubertal females with JRA, 531
- Bone morphogenetic protein receptors, in RA joint, 2046
- Bony spurs, in Achilles tendon, mechanism of formation, 576
- Brain
 fibromyalgia, regional cerebral blood flow in, 2823
 neuropsychiatric SLE, cerebral involvement by volumetric magnetization transfer imaging, 2428
 neuropsychiatric SLE, evidence of CNS damage by magnetization transfer imaging, 48
 neuropsychiatric SLE, nuclear medicine in evaluation, 1903, 1904
- Breast-feeding, postpartum relapse in women with inflammatory arthritis and RA, 1010
- Brodie's abscess, MRI imaging, 2848
- Bucillamine, T cell function in vitro, 1616
- Bursitis, olecranon bursitis presenting as Ehlers-Danlos syndrome, 714
- C**
- C-reactive protein, time-integrated levels and radiologic progression of RA, 1473
- Caffeine, reversal of antiinflammatory effects of MTX by, 656
- Calcium ions, intracellular calcium ion stores and signaling in T lymphocytes from patients with chronic inflammatory arthritis, 1257
- Calcium pentosan polysulfate
 aggrecan catabolism in articular cartilage, 2211
 metalloproteinase 3 production enhanced by, 812
- Calcium pyrophosphate, expression of IL-8 stimulated by in monocytic cells, 1145
- Carpal tunnel syndrome, from accessory lumbrical muscles, 707
- Cartilage
 adenovirus-mediated gene transfer of insulin-like growth factor 1 in proteoglycan synthesis in rabbit joints, 2563
 aggrecan catabolism in, inhibited by calcium pentosan polysulfate, 2211
 aggrecan and MMP-3 gene expression in articular chondrocytes, 2091
 chondrocyte survival in vitro mediated by autocrine stimulation by insulin-like growth factors, 1552
 CILP/NTPPH expression with aging, 2703
 cytokine gene polymorphism in OA, 2417
 degradation and invasion by rheumatoid synovial fibroblasts, plasmin inhibition, 1710
 degradation of type II collagen and proteoglycan induced by IL-1, 664
 diagnosis of OA and molecular processes in cartilage, 1425, 1426
 engineered cartilage tissue, proton magnetic resonance microscopy, 1580
 estrogen replacement therapy and chondrocyte synthesis of proteoglycans and insulin-like growth factor binding protein 2, 2081
 fibroblast-mediated degradation of modulated by articular chondrocytes in RA, 2531
 furin convertase in activation of TGF β for modulation of collagenase 3, 2100
 genetic enhancement of matrix synthesis by articular chondrocytes, growth factor genes, and IL-1, 1156
 glycosaminoglycan-degrading glycosidases and glycoside sulfatases secreted by articular chondrocytes, 1307
 hyaluronan metabolism stimulation by IL-1 α in, 1315
 hyaluronan oligosaccharides and, 1165
 immortalized human adult articular chondrocytes, 2189
 inhibition of destruction of by anti-IL-1 and anti-CD44, in vitro, 1719
 kinetics of collagen type II degradation in canine cruciate ligament transection OA model, 2121
 markers of, molecular basis and clinical use of, 953
 microscopic alterations of in rat knee joint with antigen-induced arthritis, 298
 osteogenic protein 1 and cell-associated matrix assembly by normal human articular chondrocytes, 206
 oxidative phosphorylation and chondrocyte function, 1560
 reactions to experimental wounding, apoptosis and, 215
 reduction of IL-17-induced inhibition of chondrocyte proteoglycan synthesis in by IL-4, 1300
 selective enhancement of collagenase-mediated cleavage of resident type II collagen in, 673
 sex and site differences in development of, 2543
 swelling and deformation of correlated with collagen degradation in OA, 2202
 transglutaminase in activation of latent TGF β 1 in, 1729
 up-regulation of cartilage oligomeric matrix protein in murine OA, 1742
- Cartilage oligomeric matrix protein, up-regulation in murine OA, 1742
- Caspase 3, inducible nitric oxide synthase and OA progression, 1290
- CCR5, expression in juvenile idiopathic arthritis, 765
- CD6 ligand, evidence for second CD6 ligand by synovial fibroblasts, 329
- CD16+ monocytes, in peripheral blood and synovium, correlation with joint destruction in RA, 1233
- CD18/CD11b, inflammatory infiltrates in GCA, 184
- CD18/CD11c, inflammatory infiltrates in GCA, 184

- CD35, sCR1 in gene therapy of collagen-induced arthritis, 1698
- CD40 signaling, in transgenic K/BxN mouse model of RA, 2571
- CD44
- anti-CD44 for inhibition of cartilage destruction, in vitro, 1719
 - hyaluronan metabolism stimulation by IL-1 α in articular cartilage, 1315
 - hyaluronan oligosaccharides perturb matrix homeostasis and induce chondrocytic chondrolysis, 1165
 - osteogenic protein 1 and cell-associated matrix assembly by normal human articular chondrocytes, 206
- CD54, adhesion in endothelial cells prevented by acetylcholine, 2260
- CD80, CD80-negative fibroblast-like synoviocytes and anergy in T lymphocytes, 1606
- CD95, endothelial cell apoptosis in SSc induced by antibody-dependent cell toxicity via, 2550
- Cell adhesion molecules
- decreased expression of following PM and DM treatment with corticosteroid, 336
 - inflammatory infiltrates in GCA and, 184
- Central nervous system (CNS), neuropsychiatric SLE, evidence of damage in by magnetization transfer imaging, 48
- Cervical spine subluxations, DMARDs combination therapy vs. single-DMARD therapy for RA and, 2397
- Chemokine receptors, polarized T cells expressing CCR5 and CXCR3 in juvenile idiopathic arthritis, 765
- Chemokines
- chondrocyte catabolic activity induced by, 1734
 - inflammatory, temporal expression of in rat adjuvant-induced arthritis, 1266
 - reduction of levels of in joints by TNF α blockade in RA, 38
- Children. *See also entries beginning with Juvenile*
- pediatric rheumatology in the US: strategic planning, 239
 - QT interval prolongation in asymptomatic anti-SSA/Ro-positive infants without congenital heart block, 1049
 - risk of developing AS among first-born, 2818
 - sex and site differences in cartilage development in, 2543
 - Chinese population, mannose-binding lectin and RA in, 1679
- Chlamydia pneumoniae*, in giant cell vasculitis and correlation with topographic arrangement of dendritic cells, 1543
- Chlamydia*-induced reactive arthritis, antigen-specific T cell response in by flow cytometry, 2834
- Chlorpromazine, apoptosis in activated human lymphoblasts, 1994
- Chondrocytes
- articular, 1307
 - articular, aggrecan and MMP-3 gene expression in, 2091
 - articular, fibroblast-mediated cartilage degradation modulated by in RA, 2531
 - articular, genetic enhancement of matrix synthesis by, growth factor genes and IL-1, 1156
 - articular, glycosaminoglycan-degrading glycosidases and glycoside sulfatases secreted by, 1307
 - articular, immortalized human adult articular chondrocytes, 2189
 - autocrine regulation of collagenase 3 during OA, 195
 - catabolic activity induced by chemokines, 1734
 - CILP/NTPPH and ePPi with aging, 2703
 - cytokine gene polymorphism in OA, 2417
 - hyaluronan oligosaccharides perturb matrix homeostasis and induce chondrocytic chondrolysis, 1165
 - IL-1 induction of collagenase 3 gene expression in OA, 801
 - mitochondrial oxidative phosphorylation and matrix synthesis and mineralization, 1560
 - proteoglycan and insulin-like growth factor binding protein 2 synthesis increased by estrogen replacement therapy, 2081
 - reduction of IL-17-induced inhibition of proteoglycan synthesis in cartilage by IL-4, 1300
 - response to insulin-like growth factor 1 in aging and OA, 2110
 - role in OA, 1916
- Chondrocytes (*cont'd*)
- survival in vitro, mediated by autocrine stimulation by insulin-like growth factors, 1552
- Chromosomes
- 1, 3, and 13 in SLE in BXSB mice, 349
 - X-chromosome and susceptibility to AS, 1353
- Chronic destructive oligoarthritis, associated with *Propionibacterium acnes* in patient with acne vulgaris, 2843
- Chronic inflammatory arthritis, intracellular calcium ion stores and signaling in T lymphocytes from patients with, 1257
- Chronic recurrent multifocal osteitis, evolution toward spondylarthropathy over long term, 109
- Chronic widespread pain (CWD), correlation with mental disorder, 561
- Churg-Strauss syndrome, localization of eosinophil major basic protein in damaged tissues, 1897
- Chylomicron metabolism, in SLE, 1033
- CILP/NTPPH, expression with aging, 2703
- Citrullinated peptide
- diagnostic test specific for RA, 155, 1901, 1902
 - prognostic value of anti-cyclic citrullinated peptide antibody with recent-onset RA, 1831
- cJun N-terminal kinase
- activation in RA, 2501
 - IL-1 induction of collagenase 3 gene expression in OA, 801
 - IL-8 expression stimulated by monosodium urate monohydrate and calcium pyrophosphate crystals in monocytic cells, 1145
- Clodronate liposomes, synovial macrophage depletion in RA, 1951
- Colistin, antibiotic as novel therapy for adjuvant-induced arthritis and experimental autoimmune encephalomyelitis, 2583
- Collagen
- kinetics of type II collagen degradation in OA in canine cruciate ligament transection model, 2121
 - swelling and deformation of OA cartilage correlated with collagen degradation, 2202
 - TNF α and oncostatin M levels, correlation with degradation markers of collagen and aggrecan in RA but not OA, 281
- Collagen type I
- induction of immune tolerance to in SSc by oral administration of bovine type I collagen, 1054
 - inhibition of geranylgeranyl transferase prenylation and inhibition of type I collagen gene expression in SSc fibroblasts, 1624
 - transcription factor Sp1 in SSc fibroblasts and type I collagen gene, 2240
- Collagen type II
- degradation of type II collagen and proteoglycan induced by IL-1 and collagenase, 664
 - kinetics of degradation in OA in canine cruciate ligament transection model, 2121
 - selective enhancement of collagenase-mediated cleavage of resident type II collagen in cultured OA cartilage, 673
- Collagen-induced arthritis
- adenovirus-mediated gene transfer of CTLA-4Ig fusion protein and suppression of, 1688
 - aggravated by unmethylated oligo-DNA containing CpG motifs, mouse model, 2578
 - beneficial effects of tempol in rodent model of, 320
 - comparative study of anti-TNF α , anti-CD4, and anti-TNF α /anti-CD4 for, 638
 - effect of COX gene deletion on in mice, 2687
 - expression of osteoclast differentiation factor, 821
 - human cartilage gp-39 for in DBA/1 mice, 645
 - quantitative trait loci in rat models, 1278
 - recombinant TSG-6 treatment in DBA/1J mice, 2668
 - sCR1 in gene therapy of, 1698

- Collagenase
 degradation of type II collagen and proteoglycan induced by IL-1, and collagenase inhibition, 664
 selective enhancement of collagenase-mediated cleavage of resident type II collagen in cultured OA cartilage, 673
 Collagenase 1, differential regulation of, 801
 Collagenase 3
 autocrine regulation during OA, 195
 IL-1 induction of collagenase 3 gene expression in OA, 801
 modulation in human OA cartilage, 2100
 Color Doppler sonography, inflammatory arterial stenosis, followup with, 238
 Computed tomography (CT)
 high-resolution CT in pulmonary Wegener's granulomatosis, 698
 regional cerebral blood flow in fibromyalgia, SPECT evidence, 2823
 Connective tissue diseases
 alendronate for OA in diffuse connective tissue diseases in children, 1960
 antinucleosome antibodies as markers of renal pathogenicity in, 76
 autoantibodies against dymple, 1516
 quantitative radioligand assays in, 689
 thrombosis in patients treated with cyclooxygenase inhibitors, 1891
 Corticosteroid-induced osteoporosis
 screening for osteoporosis in postmenopausal women, 1967
 vitamin D in, 1188, 1189
 Corticosteroids
 association of damage in SLE with corticosteroids, 1801
 IL-1 α , IL-1 β , and CAM expression in muscle tissue following corticosteroid treatment of PM and DM, 336
 poor-prognosis early RA, treatment with MTX, cyclosporin A, and intraarticular corticosteroids compared with sulfasalazine alone, 1809
 Corticotropin-releasing hormone, multipoint linkage analysis of *CRH* candidate gene locus in RA, 1673
 Cortisol, salivary levels in patients with recent onset RA, 465
 Cost-effectiveness studies
 prophylaxis against *Pneumocystis carinii* pneumonia in patients with Wegener's granulomatosis undergoing immunosuppressive therapy, 1841
 screening for osteoporosis in postmenopausal women with RA starting corticosteroid treatment, 1967
 treatment options for patients with MTX-resistant RA, 2316
 CpG motifs
 macrophages and induction of arthritis triggered by bacterial DNA containing, 2283
 in septic arthritis, 356
 unmethylated oligo-DNA containing and collagen-induced arthritis in mice, 2578
 Cryoglobulinemia, type II mixed, 94
 Cryptogenic fibrosing alveolitis, polymorphisms of IL-8 and CXC receptor genes in, 1633
 CTLA-4Ig fusion protein, adenovirus-mediated gene transfer of and suppression of autoimmune arthritis, 1688
 CXC receptor genes, polymorphisms of in SSc and cryptogenic fibrosing alveolitis, 1633
 CXCR3, expression in juvenile idiopathic arthritis, 765
 Cyclic citrullinated peptide, diagnostic test specific for RA, 155, 1901, 1902
 Cyclooxygenase 1 and -2 genes, effect on collagen-induced arthritis in mice, 2687
 Cyclooxygenase 2 inhibitors
 biology and clinical applications of, 4
 rofecoxib, comparison with ibuprofen and placebo on gastroduodenal mucosa, 370
 Cyclophosphamide, for Wegener's granulomatosis, 1021, 2379, 2853, 2854
 Cyclosporin A
 in antigen arthritis, 311
 for MTX-resistant RA, 2316
 for poor-prognosis early RA, treatment with MTX, cyclosporin A, and intraarticular corticosteroids compared with sulfasalazine alone, 1809
 Cystitis, in Wegener's granulomatosis patients treated with cyclophosphamide, 2853, 2854
 Cytokines. *See also entries beginning with Interferon; entries beginning with Interleukin*
 autocrine regulation of collagenase 3 during OA, 195
 autoimmune rheumatic manifestations induced by cytokine therapy, 1431
 bone erosion in RA and, 2143
 bucillamine, inhibitory effect on proinflammatory cytokine production, 1616
 cytokine gene polymorphism in OA, 2417
 cytokine-producing T cells in SLE, 711
 increased IL-17 production in patients with SSc, 2455
 macrophage-derived cytokine and NF- κ B p65 expression in patients with psoriatic arthritis, 1244
 osteoclast differentiation factor, synovial tissue as source of, 250
 in reactive arthritis, 725
 taurine chloramine inhibition of cytokine production by fibroblast-like synoviocytes in RA, 2169
 temporal expression of inflammatory cytokines in rat adjuvant-induced arthritis, 1266
 Th2-type cytokines and pulmonary fibrosis, 236
 TNF α production induced by adhered human monocytes, 608
- D**
- DBA/1 mice
 human cartilage gp-39 for collagen-induced arthritis in, 645
 sCR1 in gene therapy of collagen-induced arthritis, 1698
 T lymphocytes and enthesal ossification in, 844
 DEK oncoprotein, autoantibodies to in inflammatory disease, 85
 Dendritic cells
 antigen-presenting cells containing bacterial peptidoglycan in synovial tissue of patients with RA, 2160
Chlamydia pneumoniae in giant cell vasculitis and correlation with topographic arrangement of dendritic cells, 1543
 nuclear RelB in peripheral blood and synovial fluid cells and synovial tissue in RA, 791
 Depression, role of in outcome of fibromyalgia, 2493
 Dermal fibroblasts
 apoptosis and TGF β 1 in fibroblast selection and activation in SSc, 2230
 transcription factor CBF in SSc fibroblasts, 2219
 transcription factor Sp1 in SSc fibroblasts and type I collagen gene, 2240
 Dermatitis, nail shedding (Beau's lines) after severe gold dermatitis, 1420
 Dermatomyositis (DM)
 autoantibodies against dymple, 1516
 decreased expression of IL-1 α , IL-1 β , and cell adhesion molecules in muscle tissue following corticosteroid treatment, 336
 medium- and long-term functional outcomes in juvenile, 541
 Diabetes mellitus
 development of in child with JRA during etanercept therapy, 2606
 linkage of RA to insulin-dependent diabetes mellitus loci, 2771
 Diacerein, for knee OA, efficacy and safety, 2339
 Diclofenac sodium, clinical efficacy compared with rofecoxib, clinical trial in patients with knee and hip OA, 978
 Diffuse idiopathic skeletal hyperostosis, T cells and enthesal ossification in DBA/1 mice, 844
 Diffuse SSc
 α_2 -adrenergic constriction of isolated arterioles in, 1886

Diffuse SSc (cont'd)

- HLA-DQA1*0501 associated with in Caucasian men, 2005
- organ involvement in, 2437
- Disease-modifying antirheumatic drugs (DMARDs). *See also individual drugs*
 - bucillamine, in vitro effects, 1616
 - combination therapy vs. single-DMARD therapy, cervical spine subluxations in RA, 2397
 - survey of rheumatologists, 464
- DNA
 - antiidiotypic antibodies, cross-reactivity with in SLE, 429
 - arthritis features induced by CpG motifs in bacterial DNA, 356
 - clearance of anti-double-stranded DNA antibodies, 2265
 - collagen-induced arthritis aggravated by unmethylated oligo-DNA containing CpG motifs, mouse model, 2578
 - DNA binding activity, of C/EBP β and C/EBP δ in rheumatoid synovium, 1591
- Doppler sonography, inflammatory arterial stenosis, followup with, 238
- Drug-induced lupus erythematosus, lymphoblast apoptosis by chlorpromazine as causal factor, 1994
- Dymple, autoantibodies against in connective tissue diseases, 1516

E

- E-selectin, correlation between increased NO production and endothelial activation in SSc, 1085
- Ehlers-Danlos syndrome, presentation of as olecranon bursitis, 714
- Elderly patients. *See also Aging*
 - aspirin mini-dose effect on renal function and uric acid handling in, 103
 - mild acetabular dysplasia associated with risk of hip OA in, 400
 - reducing chondrocyte response to insulin-like growth factor 1 in aging and OA, 2110
 - systemic vasculitis, epidemiology in UK, 414
 - T cells from healthy elderly subjects suppress neutrophil development, 834
 - vascular endothelial growth factor in polymyalgia rheumatica, 2472
- Electrocardiogram analysis, QT interval prolongation in asymptomatic anti-SSA/Ro-positive infants without congenital heart block, 1049
- Encephalomyelitis, experimental autoimmune, oral antibiotics as novel therapy for, 2583
- Endostatin, in SSc, 889
- Endothelial cells
 - adhesion in endothelial cells prevented by acetylcholine, 2260
 - AECA in normal and lupus pregnancy, 1511
 - apoptosis of in SSc induced by antibody-dependent cell toxicity via CD95, 2550
 - correlation between increased NO production and markers of endothelial activation in SSc, 1085
 - leukocyte-endothelial cell interactions in GCA, 184
- Enthesal ossification, spontaneous development of in DBA/1 mice, 844
- Enthesopathy
 - AS and, 2011
 - psoriatic arthritis as enthesopathy-based disorder, 712, 713
- Enthesophytes, in Achilles tendon, mechanism of formation, 576
- Environmentally associated rheumatic disorders, identifying and defining, 243
- Epidemiology
 - systemic vasculitis in elderly patients in UK, 414
 - Wegener's granulomatosis in Norway, 2481
- Epstein-Barr virus (EBV), pathogenesis of RA and, 151, 1218, 2614
- Erythema nodosum, etiologic and predictive factors in, 584, 1061
- Erythrocyte membrane fluidity, abnormality of in SSc, 894
- Escherichia coli*, oral antibiotics as novel arthritis therapy, 2583
- Estrogen replacement therapy, chondrocyte synthesis of proteoglycans and insulin-like growth factor binding protein 2 increased by, 2081

Etanercept

- development of antibodies interfering with monoclonal antibody lab assays, 944
- for JRA children, development of diabetes mellitus during treatment, 2606
- for MTX-resistant RA, 2316
- Ethnicity
 - autosomal dominant periodic fever associated with AA amyloidosis in Indian family, 2034, 2379
 - epidemiology of Wegener's granulomatosis in Norway, 2481
 - Fcy receptor type IIIA associated with RA in two ethnic groups, 2328
 - GCA association with polymyalgia rheumatica, with different TNF microsatellite polymorphisms, Spanish population, 1749
 - hip replacement recipients less likely to be Hispanic, 390
 - inheritance of hip OA in Iceland, 2785
 - mannose-binding lectin and RA in southern Chinese, 1679
 - RA, absence of p53 mutation in Japanese patients, 469
 - RA, severity of in Portuguese patients, 470
 - RA, TNF α , TNFR II, and HLA-DRB1 polymorphisms in Japanese patients, 753
 - RA, Val68Ile polymorphism of neutrophil chemoattractant *LECT2* and, 1419
 - SLE, genetics in Italian population and association with IL-10 gene, 120, 1442
 - SLE susceptibility in populations of sub-Saharan African ancestry, 2378
 - spinal osteophytosis, TGF β 1 genotype associated in Japanese women, 452
 - SSc, TGF β and PDGF genes in Native Americans with SSc, 1068
- Etoposide, in *Staphylococcus aureus*-induced arthritis and sepsis, 2276
- Experimental autoimmune encephalomyelitis, oral antibiotics as novel therapy for, 2583
- Extended oligoarticular arthritis, low-dose oral MTX in children with, 1849
- Extracellular inorganic pyrophosphate (ePPi), expression with aging, 2703
- Extracellular MMP inducer (EMMPRIN), expression in rheumatoid synovium, 275
- Extracellular matrix proteins, anti-fibrillin 1 antibodies in SSc, 2464
- Extracellular signal-regulated kinase activation in RA, 2501
- IL-8 expression stimulated by monosodium urate monohydrate and calcium pyrophosphate crystals in monocytic cells, 1145

F

- Familial juvenile hyperuricemic nephropathy, causing underexcretion-type gout, genetics, 925
- Familial recurrent arthritis, localization of gene for, 2041
- Fas-mediated apoptosis, differential regulation of in rheumatoid synovocytes by TNF α and basic fibroblast growth factor, 1106
- Fas/Fas ligand
 - gene mutation in SLE patients, 135
 - pulmonary fibrosis and, 236
- Fcy receptor
 - in antigen-induced arthritis, 740
 - polymorphisms in SLE, 2793
- Fcy receptor type IIIA
 - associated with RA in two ethnic groups, 2328
 - genotype and RA susceptibility, 735
 - TNF α production in RA and, 608
- Felty's syndrome, neutropenia in elderly patients, 834
- Fibrillin 1, anti-fibrillin 1 antibodies in SSc, 2464
- Fibroblast-like synovocytes. *See also Synovial fibroblasts*
 - acidic fibroblast growth factor in, 2152
 - annexin I surface binding sites and, 2537

Fibroblast-like synoviocytes. *See also* Synovial fibroblasts (*cont'd*)
 CD80-negative fibroblast-like synoviocytes and anergy in T lymphocytes, 1606
 fibroblast-mediated cartilage degradation modulated by articular chondrocytes in RA, 2531
 taurine chloramine inhibition of cytokine production by in RA, 2169
 Fibroblasts. *See* Dermal fibroblasts; Synovial fibroblasts
 Fibromyalgia
 diagnosis of, responses to IL-6, 872
 in Frida Kahlo's life and art, 708
 NSAIDs over acetaminophen, patient survey, 378
 outcome, role of catastrophizing and depression in, 2493
 regional cerebral blood flow in, 2824
 Fibrosing alveolitis, polymorphisms of IL-8 and CXC receptor genes in cryptogenic, 1633
 Fibrosis
 cyclosporin A, prevention of antigen arthritis histologic damage without inducing fibrosis, 311
 Fas/Fas ligand and pulmonary fibrosis, 236
 Flow cytometry, antigen-specific T cell response in reactive arthritis by, 2834
 Fluid drainage, intraarticular hyaluronan-albumin interaction in attenuation of, 1175
 Folic acid supplementation, MTX efficacy and, 2615
 Fractures, subchondral insufficiency in rapid destruction of hip joint, 2423
 Free radical-mediated injury in pathogenesis of SS, 894
 Functional disability, correlation with pain scores rather than radiographic scores in RA, 386
 Functional iron deficiency, serum transferrin receptor and transferrin receptor ferritin index to detect in RA patients with anemia, 1016
 Furin convertase, for activation of TGF β for modulation of collagenase 3, 2100

G

G protein, mediation of monocyte chemotaxis in RA by soluble VCAM-1 mediation, 1122
 Gastrointestinal (GI) system
 comparison of rofecoxib, ibuprofen, and placebo on gastroduodenal mucosa, 370
 involvement in SS with diffuse scleroderma, 2437
 protein-losing gastroenteropathy in SLE, scintigraphic diagnosis of, 1900
 Gelatinase
 in labial salivary glands of patients with primary SS, 2807
 stimulation of MMP-9 production by IL-17 in human monocyte/macrophages, 1134
 Genant score, recombinant human IL-1Ra for RA, correlation with Larsen score, 1001
 Gene therapy
 adenovirus-mediated gene transfer of CTLA-4Ig fusion protein in suppression of autoimmune arthritis, 1688
 sCR1 in gene therapy of collagen-induced arthritis, 1698
 TNF α -induced apoptosis of human synovial fibroblasts inhibited by, 1094
 Gene transfer
 adenovirus-mediated gene transfer of CTLA-4Ig fusion protein in suppression of autoimmune arthritis, 1688
 adenovirus-mediated gene transfer of insulin-like growth factor 1 in proteoglycan synthesis in rabbit joints, 2563
 plasmin inhibitor, cartilage degradation and invasion by rheumatoid synovial fibroblasts, 1710
 Genetics. *See also* Genotype; Mutations; Polymorphism
 APS, ACE gene polymorphism and risk of arterial thrombosis in, 1655
 APS, polymorphism of plasminogen activator inhibitor gene and thrombosis in, 2349

Genetics (*cont'd*)

AS, X-chromosome and susceptibility to, 1353
 autoimmune arthritis, adenovirus-mediated gene transfer of CTLA-4Ig fusion protein in suppression of, 1688
 autosomal dominant periodic fever associated with AA amyloidosis in Indian family, 2034, 2379
 collagen-induced arthritis, effect of cyclooxygenase gene deletion on in mice, 2687
 collagen-induced arthritis, quantitative trait loci in rats, 1278
 cryptogenic fibrosing alveolitis, polymorphisms of IL-8 and CXC receptor genes in, 1633
 diffuse SSC, HLA-DQA1*0501 associated with in men, 2005
 familial juvenile hyperuricemic nephropathy causing underexcretion-type gout, 925
 familial recurrent arthritis, localization of gene for, 2041
 GCA association with polymyalgia rheumatica, with different TNF microsatellite polymorphisms, 1749
 genetic enhancement of matrix synthesis by articular chondrocytes, growth factor genes and IL-1, 1156
 glutathione S-transferase gene, 859
 HLA class II genes associated with antiphosphatidylserine/prothrombin autoantibodies, 683
 immortalized human adult articular chondrocytes, 2189
 JRA, HLA linkage demonstrated by allele sharing in affected sibling pairs, 2335
 JRA, polymorphism at *NRAMP1* and *D2S1471* loci, 1397
 Juvenile DM, TNF α -308A allele in, 2368
 MTX resistance, increased *MDRI* P-glycoprotein expression in, 1662
 OA, IL-1 induction of collagenase 3 gene expression in chondrocytes, 801
 OA, inheritance of hip, 2786
 OA, radiographic, *COL2A1* gene and susceptibility to, 1456
 OA, radiographic hip, in women, 2410
 RA, absence of p53 mutation, 469
 RA, association of TNF-region genetic markers with susceptibility to, 1366
 RA, correction of abnormal RA synovial cell function by *jun D* transfection, 945
 RA, Fc γ receptor type IIIA associated with, 2328
 RA, HLA-DRB1 polymorphisms in, 753
 RA, known and novel genes in activated monocytes, 775
 RA, linkage to insulin-dependent diabetes mellitus loci, 2772
 RA, mannose-binding lectin genotypes and radiographic outcome, 515
 RA, multipoint linkage analysis of *CRH* candidate gene locus in, 1673
 RA, noninherited maternal HLA-DR alleles and RA susceptibility, 758
 RA, polymorphism in manganese superoxide dismutase locus and disease outcome, 859
 RA, quantitative genetic contribution, data from twins, 30
 RA, Val68Ile polymorphism of neutrophil chemoattractant *LECT2* and RA in, 1419
 Raynaud's phenomenon, susceptibility loci in, 1641
 SLE, accumulated T cell clonotypes in patients with, 2712
 SLE, Fas ligand gene mutation in, 135
 SLE, Fc γ receptor polymorphisms, 2793
 SLE, IgG autoantibodies from bone marrow of patients with, 2132
 SLE, intervals on chromosomes 1, 3, and 13 in mice, 349
 SLE, in Italian population and association with IL-10 gene, 120, 1442
 SLE, restricted V β 3 gene use of intravenous immunoglobulin-selected Fab, 2722
 SLE, susceptibility in populations of sub-Saharan African ancestry, 2378
 SLE, TNF-308A and HLA-DR3 allele, contribution to susceptibility, 129

Genetics (cont'd)

- spinal osteophytosis, *TGFβ1* genotype associated in Japanese women, 452
- spondylarthropathies, familial form, 1356, 2140
- spondylarthropathies, predisposition to, 485
- spontaneous arthritis in class I-deficient mice and expression of major histocompatibility complex, 2290
- SS, frequency of t(14;18) translocation in, 951
- SSc, collagen gene expression in, 2219
- SSc, inhibition of geranylgeranyl transferase prenylation and inhibition of type I collagen gene expression in fibroblasts, 1624
- SSc, microchimerism of, 1062
- SSc, polymorphisms of IL-8 and CXC receptor genes in, 1633
- SSc, *TGFβ* and PDGF genes in Native Americans with, 1068
- TNFR1* C30S mutation linked to autosomal dominant recurrent fever with localized myositis, 1535
- Genome-wide screen, for susceptibility loci in primary Raynaud's phenomenon, 1641
- Genotype. *See also* Genetics; Mutations; Polymorphism
 - cytokine gene polymorphism in OA, 2417
 - Fcγ receptor IIIA genotype in RA susceptibility, 735
 - JRA, polymorphism at *NRAMP1* and *D2S1471* loci, 1397
 - mannose-binding lectin genotypes and radiographic outcome in RA, 515
 - TGFβ1* genotype associated with spinal osteophytosis in Japanese women, 452
 - TGFβ* and PDGF genes in Native Americans with SSc, 1068
- Geranylgeranyl transferase, inhibition of in SSc fibroblasts, 1624
- Giant cell (temporal) arteritis (GCA)
 - acute-phase response and risk of ischemic complications in, 234, 235
 - association with polymyalgia rheumatica with different TNF microsatellite polymorphisms, 1749
 - cell adhesion molecules in development of inflammatory infiltrates in, 184
 - IL-6 as marker of disease activity, 1041
 - inflammatory response in biopsy-proven GCA, 1427, 1428
- Giant cell vasculitis, *Chlamydia pneumoniae* in and correlation with topographic arrangement of dendritic cells, 1543
- Glomerulonephritis, MTX and glucocorticoids for Wegener's granulomatosis patients with, 1836
- Glucocorticoids
 - regulation of macrophage migration inhibitory factor by in rat adjuvant-induced arthritis, 827
 - for Wegener's granulomatosis patients with glomerulonephritis, 1836
- Glutathione S-transferase gene, polymorphism in manganese superoxide dismutase locus on RA outcome, 859
- Glycosidases, glycosaminoglycan-degrading glycosidases in articular chondrocytes, 1307
- Glycoside sulfatases, in articular chondrocytes, 1307
- Gold therapy, nail shedding (Beau's lines) after severe gold dermatitis, 1420
- Gonadotropin, trophoblast secretion of and invasiveness affected by antiphospholipid antibodies, 140
- Gout
 - "G" stands for gout, 1418
 - genetics of familial juvenile hyperuricemic nephropathy causing underexcretion-type gout, 925
 - IL-8 expression stimulated by monosodium urate monohydrate and calcium pyrophosphate crystals in monocytic cells, 1145
 - noninflammatory phagocytosis of monosodium urate monohydrate crystals by mouse macrophages, 1779
 - gp150,95, inflammatory infiltrates in GCA, 184
- Granulocyte colony-stimulating factor (G-CSF), autoimmune rheumatic manifestations induced by, 1438
- Granulocyte-macrophage colony-stimulating factor, autoimmune rheumatic manifestations induced by, 1438

Group B streptococcal-induced arthritis, IFNγ treatment of, 2678
 Growth factor genes, genetic enhancement of matrix synthesis by articular chondrocytes, 1156

H

- Health Assessment Questionnaire (HAQ)
 - minimally important changes in quality of life in RA clinical trials, 1478
 - RA remission/relapse and, 234
- RA treatment with leflunomide compared with MTX, 506
- reappraisal of HAQ disability in RA, 2751
- Health-related quality of life questionnaires, minimally important changes in RA clinical trials, 1478
- Heart, involvement in SSc with diffuse scleroderma, 2437
- Heat shock protein, oral administration for adjuvant-induced arthritis during disease, 2694
- Hepatitis B vaccination
 - SLE exacerbation after, 468
 - SS occurring after, 2139
- Hepatitis B virus, chronic seropositive polyarthritis and liver disease induced by, 232
- Hepatitis C virus infection
 - mimicking SLE, 2801
 - in patients with SS and non-Hodgkin's lymphoma, 1187
- Hexosaminidase, secreted by human articular chondrocytes, 1307
- Hip
 - acetabular dysplasia and risk of hip OA in elderly, 400
 - ACR recommendations for management of hip and knee OA, 1905
 - bone mineral density and hip OA, 1450
 - estrogen replacement therapy increases chondrocyte synthesis of proteoglycans and insulin-like growth factor binding protein 2, 2081
 - inheritance of hip OA in Iceland, 2785
 - OA and bone mineral density, 1450
 - quantification of progressive joint space narrowing in hip OA, 988
 - radiographic hip OA in women, 2410
 - rapidly destructive arthrosis of, 2423
 - reduced bone mineral density in male RA patients, 2776
 - rofecoxib treatment, clinical trial in patients with knee and hip OA, 978
 - subchondral insufficiency fracture in rapid destruction of hip joint, 2423
- Hip replacement, recipients less likely to be Hispanic, 390
- Hispanic population, with RA, 390
- HLA class II genes
 - antiphosphatidylserine/prothrombin autoantibodies associated with, 683
 - pauciarticular and polyarticular JRA and, 2335
- HLA-B27
 - disease outcome in *Salmonella*-infected patients modified by, 1527
 - in familial form of spondylarthropathy, 1356, 2140
 - in reactive arthritis and other spondylarthropathies, 724
- HLA-DQ, in RA susceptibility, 946, 947
- HLA-DQA1*0501, associated with diffuse SSc in Caucasian men, 2005
- HLA-DR alleles, susceptibility to SLE and, 129, 758
- HLA-DRB1 polymorphisms, in Japanese patients with RA, 753
- Hollander, Joseph Lee, in memoriam, 1430
- Human cartilage glycoprotein 39 (gp-39)
 - for collagen-induced arthritis in DBA/1 mice, 645
 - joint destruction in RA, 1233
- Human chorionic gonadotropin (HCG), suppression of streptococcal cell wall-induced arthritis by, 2064
- Hyaluronan
 - intraarticular injection for knee OA, 1192
 - intraarticular hyaluronan-albumin interaction in attenuation of fluid drainage from joints, 1175
 - intraarticular injections for pseudogout, 1660, 1661

Hyaluronan (cont'd)

- oligosaccharides perturb matrix homeostasis and induce chondrocytic chondrolysis, 1165
 - osteogenic protein 1 and cell-associated matrix assembly by normal human articular chondrocytes, 206
 - stimulation of hyaluronan metabolism by IL-1 α , 1315
- Hydralazine, antibody-positive vasculitis, prevalence in patients with high antinuclear antibody levels, 405
- Hydroxychloroquine
- combination DMARD therapy vs. single-DMARD therapy for RA, cervical spine subluxations and, 2397
 - triple therapy for patients with MTX-resistant RA, 2316
- Hypertrophic osteoarthropathy, leg pain and clubbing, 472
- Hypothalamic-pituitary-adrenal axis, response to IL-6 and fibromyalgia diagnosis, 872

I

Icelandic population, inheritance of hip OA in, 2785

Idiopathic aortitis, 901

IgG

- antinucleosome antibodies (IgG3 subclass) as markers of renal pathogenicity in SLE, 76
- autoantibodies, from bone marrow of patients with SLE, 2132
- glycosylation status as clinical predictor of RA, 2617
- restricted V_H3 gene use of intravenous immunoglobulin-selected Fab in SLE, 2722

Imaging

- anterior crural neuralgia as presenting manifestation of lymphocele, 1183
- antigen-induced arthritis, cartilage alterations in rat knee joint by ¹²⁵I-antileukoproteinase scintigraphy, 298
- Brodie's abscess, MRI, 2848
- carpal tunnel syndrome from accessory lumbrical muscles, 707
- engineered cartilage tissue, proton magnetic resonance microscopy, 1580
- gout in phalanges, 1418
- inflammatory arterial stenosis, followup with color Doppler sonography, 238
- leg pain and clubbing, 472
- Maffucci's syndrome, 1672
- MCTD presenting with pneumonitis and pneumatosis intestinalis, 704
- MRI bone erosions and bone lesions in early RA, 949, 950
- multiple myeloma presenting as shoulder pain, 2608
- muscle abnormalities in juvenile DM, P-31 MRS studies, 2359
- nail shedding (Beau's lines) after severe gold dermatitis, 1420
- neuropsychiatric SLE, 2045
- neuropsychiatric SLE, cerebral involvement by volumetric magnetization transfer imaging, 2428
- neuropsychiatric SLE, evidence of CNS damage by magnetization transfer imaging, 48
- neuropsychiatric SLE, nuclear medicine in evaluation, 1903, 1904
- OA, quantification of progressive joint space narrowing in hip OA after total hip arthroplasty, 988
- occult skin and subcutaneous abnormalities in juvenile DM, 1866
- olecranon bursitis presenting as Ehlers-Danlos syndrome, 714
- Ormond's disease, 943
- protein-losing gastroenteropathy in SLE, scintigraphic diagnosis, 1900
- psoriatic arthritis as enthesopathy-based disorder, 712, 713
- pulmonary Wegener's granulomatosis, high-resolution CT, 698
- RA, slowed radiographic progression in after treatment with, leflunomide, 495, 1345
- regional cerebral blood flow in fibromyalgia, SPECT evidence, 2823
- retroperitoneal fibrosis, 943
- Romanus spondylitis, 1186
- sonography for detection of bone erosion in RA, 2762

Imaging (cont'd)

- sonography of tendons, 969
 - stiff skin syndrome, 1542
 - tuberculous arthritis, 709
 - vasculitis in an old tattoo, 1184
 - Wegener's granulomatosis, orbital granuloma and subglottic tracheal stenosis in, 1654
 - Wegener's granulomatosis presenting as Pancoast tumor, 467
- Immortalized human adult articular chondrocytes, 2189
- Immunosuppressive therapy, cost-effectiveness of prophylaxis against *Pneumocystis carinii* pneumonia in WG patients undergoing, 1841
- Immunotherapy, autoimmune rheumatic manifestations induced by, 1438
- Improvement criteria, clinical and statistical significance of, 1658, 1659
- Indian population
- autosomal dominant periodic fever associated with AA amyloidosis in, 2034, 2379
 - Fc γ receptor type IIIA associated with RA in two ethnic groups, 2328
- Infection
- hepatitis C virus infection mimicking SLE, 2801
 - hepatitis C virus infection in patients with SS and non-Hodgkin's lymphoma, 1187
 - mannose-binding lectin deficiency and infections in patients with SLE, 1657
 - viral RNA and histologic analysis of inflamed synovium in Ross River virus, 365
- Inflammatory arthritis
- breast-feeding and postpartum relapse, 1010
 - intracellular calcium ion stores and signaling in T lymphocytes, 1257
- Inflammatory bowel disease, with arthritis, 729
- Inflammatory infiltrate
- ICAM infiltrates in GCA, 184
 - leukocyte-endothelial cell interactions in GCA, 184
- Infliximab
- anti-DNA antibodies induced by, 2381, 2383
 - anti-TNF α therapy retards synovial TNF synthesis, 2391
 - for AS, 1346
- In memoriam
- Hollander, Joseph Lee, 1430
 - Klinenberg, James R., 977
- Insulin-like growth factor binding protein 2, estrogen replacement therapy increases synthesis of, 2081
- Insulin-like growth factors
- adenovirus-mediated gene transfer of insulin-like growth factor 1 in proteoglycan synthesis in rabbit joints, 2563
 - autocrine stimulation by and in vitro chondrocyte survival, 1552
 - reducing chondrocyte response to in aging and OA, 2110
- Integrins
- aggrecan and MMP-3 gene expression in articular chondrocytes, 2091
 - superoxide production by neutrophils stimulated by β 2 integrins, 2248
- Intercellular adhesion molecule 1 (ICAM-1)
- adhesion in endothelial cells prevented by acetylcholine, 2260
 - correlation between increased NO production and markers of endothelial activation in SSc, 1085
 - functional heterogeneity of synovial cells in patients with RA, 2513
 - inflammatory infiltrates in GCA, 184
 - superoxide production by neutrophils stimulated by, 2248
- Interferon- α (IFN α), autoimmune rheumatic manifestations induced by, 1431
- Interferon- β (IFN β)
- autoimmune rheumatic manifestations induced by, 1431
 - IFN β 1 α -induced juvenile chronic arthritis in genetically predisposed patient with multiple sclerosis, 1190
 - synovial inflammation and expression of MMP in RA patients, 270

Interferon- γ (IFN γ)
 autoimmune rheumatic manifestations induced by, 1431
 effect on severity of group B streptococcal arthritis in mice, 2678

Interleukin-1 (IL-1)
 anti-IL-1 for inhibition of cartilage destruction, in vitro, 1719
 genetic enhancement of matrix synthesis by articular chondrocytes, growth factor genes and IL-1, 1156
 IL-1 induction of collagenase 3 gene expression in chondrocytes in OA, 801

Interleukin-1 receptor antagonist (IL-1Ra)
 LPS-induced arthritis, therapy and prevention by recombinant adeno-associated virus vector with, 289
 for OA, cytokine gene polymorphism, 2417
 for RA, radiologic progression and correlation of Genant and Larsen scores, 1001
 for RA in rat models, 2648

Interleukin-1 α (IL-1 α)
 anti-TNF α therapy retards synovial synthesis of, 2391
 decreased expression following myositis treatment with corticosteroid, 336
 degradation of type II collagen and proteoglycan induced by IL-1, 664
 hyaluronan metabolism stimulation by in articular cartilage, 1315

Interleukin-1 β (IL-1 β)
 anti-tumor necrosis factor α therapy retards synovial synthesis of, 2391
 cytokine gene polymorphism in OA, 2417
 decreased expression following myositis treatment with corticosteroid, 336
 diacerein for knee OA, efficacy and safety, 2339

Interleukin-2 (IL-2), autoimmune rheumatic manifestations induced by, 1435

Interleukin-4 (IL-4)
 aggrecan and MMP-3 gene expression in articular chondrocytes, 2091
 IL-17-induced inhibition of chondrocyte proteoglycan synthesis in cartilage reduced by IL-4, 1300
 regulatory effects on neutrophil function, 2660

Interleukin-6 (IL-6)
 as biologic marker of GCA disease activity, 1041
 in fibromyalgia diagnosis, 872
 taurine chloramine inhibition of cytokine production by fibroblast-like synoviocytes in RA, 2169

Interleukin-8 (IL-8)
 expression of stimulated by monosodium urate monohydrate and calcium pyrophosphate crystals in monocytic cells, 1145
 polymorphisms of IL-8 genes in SSc and cryptogenic fibrosing alveolitis, 1633
 taurine chloramine inhibition of cytokine production by fibroblast-like synoviocytes in RA, 2169

Interleukin-10 (IL-10)
 anti-IL-10 monoclonal antibody therapy in SLE, 1790
 blockade in SLE patients, 1976
 gene, association of SLE with, 120, 1442
 immortalized human adult articular chondrocytes, 2189
 regulatory effects on neutrophil function, 2660

Interleukin-12 (IL-12), RA exacerbation caused by exogenous, 461

Interleukin-17 (IL-17)
 increased production in patients with SSc, 2455
 reduction of IL-17-induced inhibition of chondrocyte proteoglycan synthesis in cartilage by IL-4, 1300
 stimulation of 92-kd gelatinase (MMP-9) production by IL-17 in human monocyte/macrophages, 1134

Intestinal flora, oral antibiotics as novel arthritis therapy, 2583

Italian population, SLE candidate genes in, 120, 1442

J

Japanese population
 RA, absence of p53 mutation in, 469
 TNF α , TNFR II, and HLA-DRB1 polymorphisms in RA, 753
 Val58I13 polymorphism of neutrophil chemoattractant *LECT2* and RA in, 1419

Joint space
 computer-based methods for measuring joint space and erosion volume in RA patients, 1378
 quantification of progressive joint space narrowing in hip OA after total hip arthroplasty, 988

jun D transfection, correction of abnormal RA synovial cell function by, in vitro, 945

Juvenile chronic arthritis
 bone mineral density in, 710
 IFN β 1 α -induced, in genetically predisposed patient with multiple sclerosis, 1190

Juvenile dermatomyositis
 medium- and long-term functional outcomes in, 541
 MRI for occult skin and subcutaneous abnormalities in, 1866
 muscle abnormalities in. P-31 MRS studies, 2359
 TNF α -308A allele in, 2368

Juvenile hyperuricemic nephropathy, causing underexcretion-type gout, 925

Juvenile idiopathic arthritis. *See also* Juvenile rheumatoid arthritis (JRA)
 extended oligoarticular or systemic arthritis, low-dose oral MTX in children with, 1849
 familial recurrent arthritis, localization of gene for, 2041
 oligoarticular-onset, long-term outcome and prognosis, 1858
 polarized T cells expressing CCR5 and CXCR3 in inflamed joints of children with, 765
 subtyping using latent class analysis, 1496

Juvenile rheumatoid arthritis (JRA). *See also* Juvenile idiopathic arthritis
 autoantibodies to DEK oncoprotein in, 85
 etanercept in children, development of diabetes mellitus during treatment, 2606
 HLA linkage demonstrated by allele sharing in affected sibpairs, 2335
 myeloid-related proteins 8 and 14 as disease markers in pauciarticular-onset, 628
 polymorphism at *NRAMP1* and *D2S1471* loci, 1397
 social, emotional, and behavioral functioning of children with, 1387
 systemic-onset, early predictors of poor functional outcome in, 2402
 total-body bone mineral content in non-corticosteroid-treated postpubertal females with, 531
 twins concordant for, 2611

Juvenile-onset SLE, nephrotic-range proteinuria as risk factor for early atherosclerosis in, 1405

K

Kidney
 accumulated T cell clonotypes in patients with SLE, 2712
 involvement in SSc with diffuse scleroderma, 2437

Klinenberg, James R., in memoriam, 977

Knee
 ACR recommendations for management of hip and knee OA, 1905
 adenovirus-mediated gene transfer of insulin-like growth factor I in rabbit, 2563
 association between varus-valgus alignment and patellofemoral OA, 1874
 diacerein for OA of, efficacy and safety, 2339
 intraarticular hyaluronan injection of in OA, 1192
 intraarticular hyaluronan-albumin interaction in attenuation of fluid drainage from, 1174

Knee (cont'd)

- microscopic cartilage alterations of in rats with antigen-induced arthritis, 298
- OA, obesity and, 568
- OA, occupational physical activities and, 1443
- OA, radiographic, *COL2A1* gene and susceptibility to, 1456
- OA, risk factors for incidence and progression of radiographic, 995
- OA, rofecoxib treatment, clinical trial in patients with, 978
- OA, sex and site differences in cartilage development, 2543

L

- L1 retrotransposable elements, in RA, 2634
- Lactoferrin, local administration and inflammation in murine autoimmune and infectious arthritis, 2073
- Large granular lymphocyte syndrome, neutropenia in elderly patients, 834
- Larsen score, recombinant human IL-1Ra for RA, correlation with Genant score, 1001
- Latent class analysis, to subtype juvenile idiopathic arthritis, 1496
- Leflunomide
 - RA treatment with, HAQ and, 506
 - RA treatment with, liver disease in patient receiving MTX and leflunomide, 2609
 - RA treatment with, modulation of inflammation and metalloproteinase expression in synovial tissue in patients with active RA, 1820
 - RA treatment with, neutrophil migration inhibition, 1488
 - RA treatment with, slowed radiographic progression, 495, 1345
- Leg pain, clubbing and, 472
- Leukocytes
 - adhesion in endothelial cells prevented by acetylcholine, 2260
 - leukocyte-endothelial cell interactions in GCA, 184
 - reduction of leukocyte traffic to joints by TNF α blockade in RA, 38
- Lipid composition, abnormalities in systemic sclerosis, 894
- Lipid peroxidation, abnormalities in systemic sclerosis, 894
- Lipocortin 1. See Annexin 1
- Lipopolysaccharide (LPS)-induced arthritis, therapy and prevention of by recombinant adeno-associated virus vector with delivery of IL-1Ra, 289
- Lipoprotein metabolism, chylomicron metabolism in SLE, 1033
- Liver disease
 - chronic seropositive polyarthritis and hepatitis B virus-induced chronic liver disease, 232
 - in patient receiving MTX and leflunomide, 2609
- Lungs, involvement in SSc with diffuse scleroderma, 2437
- Lupus anticoagulant, association of autoantibodies against with APS, 1982
- Lupus erythematosus (LE) cell phenomenon, and antichromatin antibody specificity, 420
- Lupus pregnancy, AECA in, 1511
- Lymphoblasts, chlorpromazine-induced apoptosis in activated human lymphoblasts, 1994
- Lymphocoele, anterior crural neuralgia as presenting manifestation of, 1183
- Lymphocyte function-associated antigen 1, inflammatory infiltrates in GCA, 184
- Lymphoma
 - hepatitis C virus infection in patients with SS and non-Hodgkin's lymphoma, 1187
 - salivary gland lymphomas in SS patients from rheumatoid factor B cells, 908
 - in type II mixed cryoglobulinemia, 94

M

- Mac-1, inflammatory infiltrates in GCA, 184
- Macrophage migration inhibitory factor, regulation by endogenous glucocorticoids in rat adjuvant-induced arthritis, 827

Macrophages

- antigen-presenting cells containing bacterial peptidoglycan in synovial tissue of patients with RA, 2160
- induction of arthritis triggered by bacterial DNA containing CpG motifs, 2283
- in *Staphylococcus aureus*-induced arthritis and sepsis, 2276
- stimulation of MMP-9 production by IL-17 in human monocyte/macrophages, 1134
- sulfasalazine inhibition of TNF α expression in by apoptosis, 1941
- synovial macrophage depletion with clodronate-containing liposomes in RA, 1951
- Macrophagic myofasciitis (MMF), gallium-56 scintigraphy in, 1520
- Maffucci's syndrome, 1672
- Magnetic resonance imaging (MRI)
 - anterior crural neuralgia as presenting manifestation of lymphocoele, 1183
 - bone erosions and bone lesions in early RA, 949, 950
 - Brodie's abscess, 2848
 - of engineered cartilage, 1581
 - multiple myeloma presenting as shoulder pain, 2608
 - for occult skin and subcutaneous abnormalities in juvenile dermatomyositis, 1866
- Magnetic resonance spectroscopy, P-31, muscle abnormalities in juvenile DM, 2359
- Magnetization transfer imaging
 - neuropsychiatric SLE, assessing cerebral involvement by, 2428
 - neuropsychiatric SLE, evidence of CNS damage by, 48
- Major basic protein, localization of in damaged tissues in Churg-Strauss syndrome, 1897
- Major histocompatibility complex
 - SLE susceptibility in populations of sub-Saharan African ancestry, 2378
 - spontaneous arthritis in class I-deficient mice and expression of, 2290
- Manganese superoxide dismutase locus, polymorphism in and RA outcome, 859
- Mannose-binding lectin
 - deficiency and infections in patients with SLE, 1657
 - deficiency and RA and in southern Chinese, 1679
- Mannose-binding lectin gene, polymorphisms in, lack of association with primary SS, 2851
- Mantoux test, false-positive results in Behcet's syndrome, 2855
- Markers
 - autosomal dominant periodic fever associated with AA amyloidosis, 2034, 2379
 - connective tissue diseases, dymple as marker, 1516
 - in GCA, IL-6 as biologic marker of disease activity, 1041
 - in MCTD, antinucleosome antibodies as markers of renal pathogenicity, 76
 - molecular basis and clinical use of markers of bone, cartilage, and synovium, 953
 - in murine OA, cartilage oligomeric matrix protein and, 1742
 - pauciarticular-onset JRA, myeloid-related proteins 8 and 14 as, 628
 - in RA, ANCA as early marker, 1371
 - in RA, association of TNF-region genetic markers with susceptibility, 1366
 - in RA, degradation markers of collagen and aggrecan, 281
 - in SSc, anti-topo I antibody, 1074, 2733
 - in SSc, correlation between increased NO production and markers of endothelial activation, 1085
- Mast cells, TNF α and chemotaxis, 164
- Matrilin-1
 - association with OA, 1423, 1424
 - autoreactivity against in relapsing polychondritis, 939
- Matrix metalloproteinase (MMP)
 - autocrine regulation of collagenase 3 during OA, 195
 - collagen type II cleavage inhibition, 673

Matrix metalloproteinase (MMP) (*cont'd*)

- EMMPRIN in rheumatoid synovium, 275
- expression pattern of membrane-type in RA, 1226
- IFN β treatment of RA and expression of, 270
- IL-1 induction of collagenase 3 gene expression in OA, 801
- in labial salivary glands of patients with primary SS, 2807
- MMP 3 gene expression in articular chondrocytes, 2091
- MMP 3 as predictor of joint destruction in RA, 2614, 2615
- MMP 3 production enhancement by calcium pentosan polysulfate, 812
- as predictor of degree of joint destruction, 852, 2614, 2615
- stimulation of MMP 9 production by IL-17 in human monocyte/macrophages, 1134
- suppression of MMP 9 in SS by adding inhibitor of NF- κ B α cDNA, 1756
- Mechanotransduction, aggrecan and MMP-3 gene expression in articular chondrocytes, 2091
- Membrane-targeted complement regulator, in antigen-induced arthritis, 2590
- Membrane-type MMP, expression pattern in RA, 1226
- Methotrexate (MTX)
 - antiinflammatory effects of reversed by theophylline and caffeine, 656
 - combination DMARD therapy vs. single-DMARD therapy for RA, cervical spine subluxations and, 2397
 - disease duration and response to treatment in RA, 22
 - folic acid supplementation and, 2615
 - inhibition of neutrophil migration after initiation of treatment in RA, 1488
 - liver disease in patient receiving MTX and leflunomide for RA, 2609
 - low-dose oral in children with extended oligoarticular or systemic arthritis, 1849
 - modulation of inflammation and metalloproteinase expression in synovial tissue in active RA, 1820
 - poor-prognosis early RA, treatment with MTX, cyclosporin A, and intraarticular corticosteroids compared with sulfasalazine alone, 1809
 - reduced mortality in patients with severe RA, 14, 1902, 1903
 - renal failure as risk factor, 1185
 - resistance, increased *MDR1* P-glycoprotein expression in, 1662
 - treatment options for RA patients with, 2316
 - in Wegener's granulomatosis patients with glomerulonephritis, 1836
- Microchimerism
 - in SSc patients, 1062
 - vinyl chloride and dermal fibrosis in microchimeric mice, 2598
- Microsatellites
 - GCA association with polymyalgia rheumatica, with different TNF microsatellite polymorphisms, 1749
 - SSc, TGF β and PDGF genes in Native Americans, 1068
- Minocycline, ANCA seroconversion induced by, 2488
- Mitochondria, oxidative phosphorylation and chondrocyte function, 1560
- Mitogen-activated protein kinase (MAPK)
 - and disease-modifying activity of SB 242235 in adjuvant arthritis, 175
 - IL-8 expression stimulated by monosodium urate monohydrate and calcium pyrophosphate crystals in monocytic cells, 1145
 - SAPK/MAPK activation/localization/regulation in RA, 2501
- Mixed connective tissue disease (MCTD)
 - antinucleosome antibodies as markers of renal pathogenicity in, 76
 - presenting with pneumonitis and pneumatosis intestinalis, 704
- Mixed cryoglobulinemia, oligoclonal non-neoplastic B cell expansion as key feature of, 94
- Monkey models, reducing chondrocyte response to insulin-like growth factor 1 in aging and OA, 2110
- Monoclonal antibodies. *See also under individual antibodies*
 - to Fc γ R, cytokine production in RA, 608

Monoclonal antibodies. *See also under individual antibodies (cont'd)*
infliximab for ankylosing spondylitis, 1346

Monocytes

- human cartilage gp-39 and CD16+ monocytes in, correlation with joint destruction in RA, 1233
- IL-8 expression stimulated by monosodium urate monohydrate and calcium pyrophosphate crystals in, 1145
- known and novel genes in activated monocytes from RA patients, 775
- mediation of chemotaxis in RA by soluble VCAM-1 mediation, 1122
- in *Staphylococcus aureus*-induced arthritis and sepsis, 2276
- stimulation of MMP-9 production by IL-17 in, 1134
- Monosodium urate monohydrate crystals
 - expression of IL-8 stimulated by in monocytic cells, 1145
 - noninflammatory phagocytosis of by mouse macrophages, 1779
- Mouse models
 - adenovirus-mediated gene transfer of CTLA-4Ig fusion protein and suppression of autoimmune arthritis, 1688
 - antimuscarinic acetylcholine receptor antibody-mediated secretory dysfunction in NOD mice, 2297
 - arthritis features induced by CpG motifs in bacterial DNA, 356
 - arthritis suppression and protection from bone destruction with TNP-470/AGM-1470 in RA, 2056
 - CD40 and TNF α signaling in K/BxN mouse model of RA, 2571
 - collagen-induced arthritis, comparative study of anti-TNF α , anti-CD4, and anti-TNF α /anti-CD4 for, 638
 - collagen-induced arthritis, effect of cyclooxygenase gene deletion on, 2687
 - collagen-induced arthritis, human cartilage gp-39 for, 645
 - collagen-induced arthritis, recombinant TSG-6 treatment of, 2668
 - collagen-induced arthritis, sCR1 in gene therapy for, 1698
 - collagen-induced arthritis, unmethylated oligo-DNA containing CpG motifs and, 2578
 - degradation and invasion by rheumatoid synovial fibroblasts, plasmin inhibition, 1710
 - fibroblast-mediated cartilage degradation modulated by articular chondrocytes in RA, 2531
 - lactoferrin local administration and inflammation in autoimmune and infectious arthritis, 2073
 - macrophages and induction of arthritis triggered by bacterial DNA containing CpG motifs, 2283
 - noninflammatory phagocytosis of monosodium urate monohydrate crystals by macrophages, 1779
 - SLE, intervals on chromosomes 1, 3, and 13, 349
 - spontaneous arthritis in class I-deficient mice, 2290
 - T cells and enthesal ossification in DBA/1 mice, 844
 - up-regulation of cartilage oligomeric matrix protein in OA, 1742
 - vinyl chloride causes dermal fibrosis in microchimeric mice, 2598
- Multicentric reticulohistiocytosis, 930
- Multiple myeloma, presenting as shoulder pain, 2608
- Multiple sclerosis, IFN β 1 α -induced juvenile chronic arthritis in, 1190
- Muscarinic receptor autoantibodies, inhibitory effects of on parasympathetic neurotransmission in SS, 1647
- Muscles
 - abnormalities in juvenile dermatomyositis patients, P-31 MRS studies, 2359
 - carpal tunnel syndrome from accessory lumbrical muscles, 707
 - decreased expression of IL-1 α , IL-1 β , and cell adhesion molecules following treatment of PM and DM, 336
 - gallium-56 scintigraphy in macrophagic myofasciitis, 1520
- Mutations. *See also Genetics; Genotype; Polymorphism*
 - absence of p53 mutation in Japanese RA patients, 469
 - Fas ligand gene mutation in SLE, 135
 - TNFR1* C30S mutation linked to autosomal dominant recurrent fever with localized myositis, 1535
- Myelodysplasia, in Wegener's granulomatosis patients treated with cyclophosphamide, 2853, 2854
- Myeloid-related proteins 8 and 14, as disease markers in pauciarticular-onset JRA, 628

Myositis, decreased expression of IL-1 α , IL-1 β , and cell adhesion molecules in muscle tissue following corticosteroid treatment, 336

N

- Nail shedding, after severe gold dermatitis, 1420
Native American population, SSc, TGF β and PDGF genes in, 1068
Natural killer cells, 1204, 1442
Neonate, QT interval prolongation in asymptomatic anti-SSA/Ro-positive infants without congenital heart block, 1049
Nephropathy
 familial juvenile hyperuricemic, causing underexcretion-type gout, 925
 MTX and glucocorticoids in Wegener's granulomatosis patients with, 1836
 in SSc with diffuse scleroderma, 2437
Neuralgia, anterior crural as presenting manifestation of lymphocoele, 1183
Neuropsychiatric SLE
 cerebral involvement by volumetric magnetization transfer imaging, 2428
 evidence of CNS damage by magnetization transfer imaging, 48
 imaging, 48, 2045, 2428
 nuclear medicine in evaluation, 1903, 1904
Neutropenia, in Felty's and large granular lymphocyte syndromes, 834
Neutrophils
 inhibition of migration after initiation of leflunomide or MTX treatment of RA, 1488
 regulatory effects of IL-4 and IL-10 on, 2660
 superoxide production by, 2248
 treatment of rolling neutrophils with ANCA, 1337
Nitric oxide (NO)
 correlation between increased NO production and markers of endothelial activation in SSc, 1085
 focal adhesion complex assembly in endothelial cells prevented by acetylcholine via, 2260
 mitochondrial oxidative phosphorylation as downstream regulator of NO effects on chondrocytes, 1560
Nitric oxide synthase, inhibition of in experimental OA, 1290
Non-Hodgkin's lymphoma, hepatitis C virus infection in patients with SS and, 1187
Noninflammatory phagocytosis, of monosodium urate monohydrate crystals by macrophages in gout, 1779
Noninherited maternal antigens and RA susceptibility in Europe, 758
Nonsteroidal antiinflammatory drugs (NSAIDs)
 preference over acetaminophen, occurrence and cost of GI side effects, 917
 preference over acetaminophen, survey of OA, RA, and fibromyalgia patients, 378
Norwegian population, epidemiology of Wegener's granulomatosis in, 2481
Nuclear factor κ B (NF- κ B)
 IL-1 induction of collagenase 3 gene expression in OA, 801
 IL-8 expression stimulated by monosodium urate monohydrate and calcium pyrophosphate crystals in monocytic cells, 1145
 macrophage-derived cytokine and NF- κ B p65 expression in patients with psoriatic arthritis, 1244
 osteoclastogenesis from synovocytes in RA, 259
 suppression of MMP-9 in SS by adding inhibitor of NF- κ B cDNA, 1756
Nuclear RelB, in peripheral blood and synovial fluid cells and synovial tissue in RA patients, 791
Nucleosomes, as major T and B cell autoantigens in SLE, 2307

O

- Obesity, knee OA and varus malalignment, 568
Olecranon bursitis, presentation of Ehlers-Danlos syndrome as, 714

- Oligoarthritis, chronic destructive oligoarthritis associated with *Propionibacterium acnes* in acne vulgaris, 2843
Oligoarticular-onset juvenile idiopathic arthritis
 long-term outcome and prognosis, 1858
 low-dose oral MTX in children with, 1849
Oncostatin M, correlation with degradation markers of collagen and aggrecan in RA but not OA, 281
Orbital granuloma, in Wegener's granulomatosis, 1654
Ormond's disease, diagnosis and treatment of, 943
Osteitis, evolution of chronic recurrent multifocal toward spondylarthropathy, 109
Osteoarthritis (OA)
 acetabular dysplasia associated with risk of hip OA in elderly, 400
 ACR recommendations for management of hip and knee OA, 1905
 aggrecan catabolism in cartilage inhibited by calcium pentosan polysulfate, 2211
 aggrecan and MMP-3 gene expression in articular chondrocytes, 2091
 annexin I surface binding sites and regulation on fibroblast-like synovocytes, 2437
 association between varus-valgus alignment and patellofemoral OA, 1874
 association of matrilin-1 gene with, 1423, 1424
 autocrine regulation of collagenase 3 during, 195
 chondrocyte catabolic activity induced by chemokines, 1734
 chondrocytes, role in, 1916
 cytokine gene polymorphism in, 2417
 diacerein for knee OA, efficacy and safety, 2339
 diagnosis of and molecular processes in cartilage, 1425, 1426
 estrogen replacement therapy and, 2081
 furin convertase in activation of TGF β for modulation of collagenase 3, 2100
 glycosidase and glycoside sulfatase profile in synovial fluid, 1307
 hip OA and bone mineral density, 1450
 IL-1 induction of collagenase 3 gene expression in chondrocytes, 801
 inheritance of hip OA in Iceland, 2785
 inhibition of inducible nitric oxide synthase and progression of, 1290
 intraarticular hyaluronan injection for, 1192
 kinetics of type II collagen degradation in canine cruciate ligament transection model, 2121
 mitochondrial oxidative phosphorylation and chondrocyte function, 1560
 NSAIDs over acetaminophen, 378, 917
 obesity and knee OA, malalignment and, 568
 occupational physical activities and knee OA, 1443
 osteoblastic cells, cellular activity and replicative capacity of in RA compared with OA, 2178
 osteogenic protein 1 and cell-associated matrix assembly by normal human articular chondrocytes, 206
 predictive value of OA diagnoses in administrative database, 1881
 quantification of progressive joint space narrowing in hip OA after total hip arthroplasty, 988
 radiographic, COL2A1 gene and susceptibility to, 1456
 radiographic hip OA in women, 2410
 radiographic knee OA, risk factors, 995
 reducing chondrocyte response to insulin-like growth factor 1 in, 2110
 rofecoxib treatment of, clinical trial in patients with knee and hip OA, 370, 978
 selective enhancement of collagenase-mediated cleavage of resident type II collagen in cultured OA cartilage, 673
 sex and site differences in cartilage development, 2543
 swelling and deformation of OA cartilage correlated with collagen degradation, 2202
 TNF α and oncostatin M levels, correlation with degradation markers of collagen and aggrecan in RA but not OA, 281
 TNF α and stem cell factor expression in, 164

Osteoarthritis (OA) (*cont'd*)
 up-regulation of cartilage oligomeric matrix protein in murine, 1742
 Osteoblastic cells, cellular activity and replicative capacity of in patients with RA compared with OA, 2178
 Osteoclast differentiation factor
 osteoclastogenesis from synoviocytes in RA, 259, 2523
 in RA, 2523
 at sites of bone erosion in collagen-induced arthritis, 821
 synovial tissue as source of in RA, 250
 Osteogenic protein 1, cell-associated matrix assembly by normal human articular chondrocytes and, 206
 Osteopenia
 alendronate for OA in diffuse connective tissue diseases in children, 1960
 in juvenile arthritis, 1504
 total-body bone mineral content in non-corticosteroid-treated postpubertal females with JRA, 531
 Osteopontin, in RA, 1597
 Osteoporosis
 alendronate for in diffuse connective tissue diseases in children, 1960
 in JRA, total-body bone mineral content in non-corticosteroid-treated postpubertal females with, 531
 in juvenile arthritis, 1504
 in RA, bone mineral density and frequency of in females with, 522
 in RA, reduced bone mineral density in males with, 2776
 in RA, screening for in postmenopausal women starting corticosteroid treatment, 1967
 vitamin D in corticosteroid-induced osteoporosis, 1188, 1189
 Ovulation induction and in vitro fertilization in patients with SLE and APS, 550, 2380
 Oxidative phosphorylation, chondrocyte function and, 1560

P

p38, for IL-1 induction of collagenase 3 gene expression in OA, 801
 p38 MAPK, activation in RA, 2501
 p53 mutation, absence of in Japanese RA patients, 469
 P-31 magnetic resonance spectroscopy, muscle abnormalities in juvenile DM, 2359
 Pain
 correlation with functional disability in RA, 386
 correlation with mental disorder, 561
 fibromyalgia, role of catastrophizing pain in outcome of, 2493
 Pakistani population, Fcγ receptor type IIIA associated with RA in two ethnic groups, 2328
 Pancoast tumor, Wegener's granulomatosis presenting as, 467
 Patelofemoral OA, association between varus-valgus alignment and, 1874
 Pauciarticular-onset JRA
 HLA class II alleles and, 2335
 myeloid-related proteins 8 and 14 as disease markers in, 628
 Pediatric rheumatology, strategic planning in US, 239
 Penicillamine
 ANCA seroconversion induced by, 2488
 antibody-positive vasculitis, prevalence in patients with high antinuclear antibody levels, 405
 Peptidoglycan, antigen-presenting cells containing bacterial in RA synovial tissue, 2160
 Phosphatidylserine-prothrombin complex, association of autoantibodies against with APS and lupus anticoagulant, 1982
 Phosphoproteins, SR proteins as autoantigens in SLE, 1768
 Pisetsky, David S., new Editor of *Arthritis & Rheumatism*, 1429
 Plasmin inhibitor, degradation and invasion by rheumatoid synovial fibroblasts, 1710
 Plasminogen activator inhibitor, gene polymorphism and thrombosis in APS, 2349
 Platelet-derived growth factor (PDGF), genes in Native Americans with SSc, 1068
 Platelet endothelial cell adhesion molecule 1, inflammatory infiltrates in GCA, 184
 Pneumatosis intestinalis, MCTD presenting with, 704
Pneumocystis carinii pneumonia, cost-effectiveness of prophylaxis against in Wegener's granulomatosis patients undergoing immunosuppressive therapy, 1841
 Pneumonitis, MCTD presenting with, 704
 Poetry, 2138
 Poly(ADP)-ribose polymerase, SLE and PAPS susceptibility, 1421, 1422
 Polyarticular JRA
 diabetes mellitus during etanercept treatment of, 2606
 HLA class II alleles and, 2335
 Polychondritis, autoreactivity against matrilin-1 in relapsing, 939
 Polymorphism. *See also* Genetics; Genotype; Mutations
 angiotensin-converting enzyme gene polymorphism and risk of arterial thrombosis in APS, 1655
 association of GCA with polymyalgia rheumatica with different TNF microsatellite polymorphisms, 1749
 cytokine gene polymorphism in OA, 2417
 FCγRIIIA, in RA, 735
 HLA-DRB1 polymorphisms in RA, 753
 of IL-8 and CXCR2 receptor genes in SSc and cryptogenic fibrosing alveolitis, 1633
 of mannose-binding lectin gene, association with primary SS, 2851
 at *NRAMP1* and *D2S1471* loci associated with JRA, 1397
 of plasminogen activator inhibitor gene and thrombosis in APS, 2349
 of TGFβ and PDGF genes in Native Americans with SSc, 1068
 Val68Ile polymorphism of neutrophil chemoattractant *LECT2* and RA in Japanese population, 1419
 Polymyalgia rheumatica
 association with GCA with different TNF microsatellite polymorphisms, 1749
 vascular endothelial growth factor production in, 2472
 Polymyositis (PM), decreased expression of IL-1α, IL-1β, and cell adhesion molecules in muscle tissue following corticosteroid treatment, 336
 Portuguese population, severity of RA in, 470
 Prednisolone, combination DMARD therapy vs. single-DMARD therapy for RA, cervical spine subluxations and, 2397
 Prednisone, association of damage in SLE with, 1801
 Pregnancy
 AECA in normal and lupus pregnancy, 1511
 HCG and suppression of streptococcal cell wall-induced arthritis, 2064
 postpartum relapse and breast-feeding in women with RA and inflammatory arthritis, 1010
 RA remission/relapse, HAQ and, 234
 trophoblast gonadotropin secretion and invasiveness affected by antiphospholipid antibodies, 140
 Primary antiphospholipid syndrome (PAPS)
 increased sVCAM concentrations and severity of thrombosis in, 55
 ovulation induction and in vitro fertilization in patients with, 550
 poly(ADP)-ribose polymerase and susceptibility, 1421, 1422
 Primary Raynaud's phenomenon, susceptibility loci in, 1641
 Primary SS
 expression of matrix metalloproteinases in labial salivary gland of patients with, 2807
 mannose-binding lectin gene polymorphisms and, 2851
Propionibacterium acnes, chronic destructive oligoarthritis associated with in patient with acne vulgaris, 2843
 Propylthiouracil, antibody-positive vasculitis, prevalence in patients with high antinuclear antibody levels, 405

Protein kinase C, mediation of monocyte chemotaxis in RA by soluble VCAM-1, 1122

Protein S, anti-protein S antibodies in patients with SLE, 557

Proteinuria, nephrotic-range, as risk factor for early atherosclerosis in juvenile-onset SLE, 1405

Proteoglycan
adenovirus-mediated gene transfer of insulin-like growth factor 1 in rabbit joints, 2563
degradation of type II collagen and proteoglycan induced by IL-1 and collagenase, 664
estrogen replacement therapy increases synthesis of, 2081
reduction of IL-17-induced inhibition of chondrocyte synthesis by IL-4, 1300

Prothrombin, association of autoantibodies against phosphatidylserine-prothrombin complex with APS and lupus anticoagulant, 1982

Proton magnetic resonance microscopy, of engineered cartilage tissue, 1580

Pseudogout
IL-8 expression stimulated by monosodium urate monohydrate and calcium pyrophosphate crystals in monocytic cells, 1145
intraarticular hyaluronate injections, 1660, 1661

Psoriatic arthritis
as enthesopathy-based disorder, 712, 713
joint symmetry in, 865
macrophage-derived cytokine and NF- κ B p65 expression in patients with, 1244

Psychosocial morbidity, in children with JRA, 1387

Pulmonary disease
Fas/Fas ligand and pulmonary fibrosis, 236
high-resolution CT of in Wegener's granulomatosis, 698
MCTD presenting with pneumonitis and pneumatosis intestinalis, 704
organ involvement in SSc with diffuse scleroderma, 2437

Q

Quality of life, health-related quality of life questionnaires in RA clinical trials, 1478

Quantitative radioligand assays, with de novo-synthesized recombinant autoantigens in connective tissue diseases, 689

Questionnaire, health status. *See* Health Assessment Questionnaire (HAQ)

R

Rabbit models
adenovirus-mediated gene transfer of insulin-like growth factor 1 in proteoglycan synthesis in, 2563
genetic enhancement of matrix synthesis by articular chondrocytes, 1156
intraarticular hyaluronan-albumin interaction in attenuation of fluid drainage from joints, 1174

Radical scavengers, tempol, beneficial effects in rodent model of collagen-induced arthritis, 320

Radiography
anterior crural neuralgia as presenting manifestation of lymphocele, 1183
OA of knee, risk factors for incidence and progression of radiographic disease, 995
RA, correlation of functional disability with pain scores rather than radiographic scores, 386
RA, damage during first six years of, 1927
RA, leflunomide and, 495, 1345
RA, mannose-binding lectin genotypes and radiographic outcome in, 515
RA, recombinant human IL-1Ra treatment of, correlation of Genant and Larsen scores, 1001
RA, scoring systems for long-term assessment of, 1465

Radiography (cont'd)

RA, time-integrated C-reactive protein levels and, 1473

Rat models

bony spurs in Achilles tendon, mechanism of formation, 576
expression of osteoclast differentiation factor at bone erosion sites in collagen-induced arthritis, 821
IL-1Ra and soluble TNFR type I treatment of RA, 2648
kinetics of type II collagen degradation in OA in canine cruciate ligament transection model, 2121
membrane-targeted complement regulator in antigen-induced arthritis, 2590
microscopic cartilage alterations in rat knee joint with antigen-induced arthritis, 298
oral antibiotics as novel arthritis therapy, 2583
oral mycobacterial Hsp65 for adjuvant-induced arthritis during disease, 2694
quantitative trait loci in collagen-induced arthritis, 1278
regulation of macrophage migration inhibitory factor in adjuvant-induced arthritis, 827
regulatory effects of IL-4 and IL-10 on neutrophil function in, 2660
reversal of antiinflammatory effects of MTX by theophylline and caffeine in adjuvant arthritis, 656
SB 242235 disease-modifying activity in adjuvant arthritis, 175
tempol, beneficial effects in collagen-induced arthritis, 320
temporal expression of inflammatory cytokines and chemokines in adjuvant-induced arthritis, 1266
therapy and prevention of LPS-induced arthritis by recombinant adeno-associated virus vector with delivery of IL-1 receptor antagonist, 289

Raynaud's phenomenon, susceptibility loci in, 1641

Reactive arthritis
antigen-specific T cell response in by flow cytometry, 2835
Fourth International Workshop, conference summary, 720
Receptor activator, of nuclear factor κ B ligand/osteoclast differentiation factor in RA, 259
Recombinant adeno-associated virus vector, therapy and prevention of LPS-induced arthritis by with delivery of IL-1Ra, 289
Recombinant autoantigens, quantitative radioligand assays with in connective tissue diseases, 689
Regional cerebral blood flow, in fibromyalgia, 2823
Regulatory CD4⁺ T cell subset, correlation with Th1/Th2 balance and RA severity, 617

Relapse
RA, HAQ and, 234
RA, postpartum relapse and breast-feeding in women with RA and inflammatory arthritis, 1010
Wegener's granulomatosis, prediction by measurement of ANCA levels, 2025

Relapsing polychondritis, autoreactivity against matrilin-1 in, 939

Renal function
aspirin mini-dose effect on renal function and uric acid handling in elderly, 103
MTX and glucocorticoids for Wegener's granulomatosis patients with glomerulonephritis, 1836
organ involvement in SSc with diffuse scleroderma, 2437
renal failure as risk factor of MTX treatment, 1185
Retroperitoneal fibrosis, diagnosis and treatment of, 943
Retroviruses, L1 retrotransposable element in RA, 2634

Rheumatoid arthritis (RA)
acidic fibroblast growth factor in synovocytes, 2152
ACR 20% criteria for improvement in, 2743
ANCA as early marker, 1371
anemia with, serum transferrin receptor and transferrin receptor ferritin index to detect, 1016
annexin I surface binding sites and regulation on fibroblast-like synovocytes, 2437

Rheumatoid arthritis (RA) (cont'd)

anti-cyclic citrullinated peptide antibody, prognostic value of in recent-onset disease, 1831
antigen-presenting cells containing bacterial peptidoglycan in synovial tissue, 2160
antiperinuclear factor and antikeratin antibody in diagnosis, 2618
anti-TNF α induction of anti-DNA autoantibodies, 2381, 2383
anti-TNF α therapy retards synovial TNF synthesis, 2391
association of TNF-region genetic markers with susceptibility, 1366
bacterial DNA and bacterial peptidoglycans in RA joints, 593, 1061
bone erosion in, cellular mechanisms and role of cytokines in, 2143
bone morphogenetic protein receptors in, 2046
breast-feeding and postpartum relapse, 1010
bucillamine, T cell function in vitro, 1616
C-reactive protein levels and radiologic progression, 1473
C/EBP β and C/EBP δ in synovium in, 1591
calcium pentosan polysulfate treatment of, MMP-3 production enhanced by, 812
CD80-negative fibroblast-like synoviocytes and anergy in T lymphocytes, 1606
combination DMARD therapy vs. single-DMARD therapy, cervical spine subluxations and, 2397
computer-based methods for measuring joint space and erosion volume in finger and wrist joints in, 1378
correction of abnormal synovial cell function by *jun* D transfection in vitro, 945
cyclic citrullinated peptide in, 155, 1901, 1902
degradation and invasion by rheumatoid synovial fibroblasts, plasmin inhibition, 1710
disease-modifying activity of SB 242235 in adjuvant arthritis, 175
DMARD therapy, survey of rheumatologists, 464
early diagnosis of, 473
EBV and pathogenesis of, 151, 1218, 2614
etanercept treatment of, development of antibodies interfering with monoclonal antibody assays, 944
exacerbation caused by exogenous IL-12, 461
expression pattern of membrane-type MMP in, 1226
extracellular MMP inducer in synovium in, 275
Fas-mediated apoptosis, differential regulation of in rheumatoid synoviocytes by TNF α and basic fibroblast growth factor, 1106
Fc γ receptor IIIA genotype in susceptibility, 735
Fc γ receptor type IIIA associated with in two ethnic groups, 2328
fibroblast-mediated cartilage degradation modulated by articular chondrocytes in, 2531
functional disability in, 386
functional heterogeneity of synovial cells, 2513
genetic contribution, data from twins, 30
gp-39 in, 645
HCG and amelioration in pregnancy, 2064
health-related quality of life questionnaires for minimally important changes in clinical trials, 1478
HLA-DQ in susceptibility, 946, 947
HLA-DRB1 polymorphisms in Japanese patients, 753
human cartilage gp-39 and joint destruction in, 1233
IFN β treatment of, effect of on synovial inflammation and matrix metalloproteinases in, 270
IgG glycosylation status as clinical predictor of, 2617
IL-1Ra and soluble TNFR type I treatment, rat model, 2648
induction of TNF α production by adhered human monocytes, 608
infliximab treatment of, anti-DNA antibodies induced by, 2381, 2383
inhibition of cartilage destruction by anti-IL-1 and anti-CD44, in vitro, 1719
insulin-dependent diabetes mellitus loci, linkage of RA to, 2771
joint symmetry in, 865
known and novel genes in activated monocytes from RA patients, 775

Rheumatoid arthritis (RA) (cont'd)

lactoferrin local administration and inflammation in murine autoimmune and infectious arthritis, 2073
leflunomide treatment of, 495, 506, 1345, 1488, 1820, 2609
liver disease in patient receiving MTX and leflunomide, 2609
mannose-binding lectin genotypes and radiographic outcome in, 515
mannose-binding lectin and RA in southern Chinese, 1679
mediation of monocyte chemotaxis in by soluble VCAM-1 mediation, 1122
MMP-3 as predictor of joint destruction, 852, 2614
MMP in, 270, 1226, 2614
MRI bone erosions and bone lesions in early RA, 949, 950
MTX treatment of, 14, 22, 495, 506, 1345, 1902, 1903
MTX treatment of, folic acid supplementation and MTX efficacy, 2615
MTX treatment of, inhibition of neutrophil migration after initiation of treatment, 1488
MTX treatment of, liver disease in patient receiving MTX and leflunomide, 2609
MTX treatment of, modulation of inflammation and metalloproteinase expression in synovial tissue, 1820
MTX treatment of, renal failure as risk, 1185
multipoint linkage analysis of *CRH* candidate gene locus in, 1673
noninherited maternal antigens and RA susceptibility in Europe, 758
NSAIDs over acetaminophen, occurrence and cost of GI side effects, 917
NSAIDs over acetaminophen, patient survey, 378
nuclear RelB in peripheral blood and synovial fluid cells and synovial tissue in, 791
osteoblastic cells, cellular activity and replicative capacity of, compared with OA, 2178
osteoclast differentiation factor, expression of, 259, 2523
osteoclastogenesis from synoviocytes, 259, 2523
osteopontin messenger RNA and protein in, 1597
osteoporosis, bone mineral density and frequency of in female patients, 522
p53 mutation absent in Japanese patients, 469
polymorphism in manganese superoxide dismutase locus and disease outcome, 859
poor-prognosis early disease, treatment with MTX, cyclosporin A, and intraarticular corticosteroids compared with sulfasalazine alone, 1809
in Portuguese patients, severity of, 470, 471
prevention of in K/BxN mice by anti-CD40 ligand, 2571
radiologic damage during first six years of, 1927
radiologic scoring systems for long-term assessment of, 1465
reappraisal of HAQ disability in, 2751
recombinant human IL-1Ra treatment, radiologic progression and correlation of Genant and Larsen scores, 1001
reduced bone mineral density in male patients, 2776
reduction of IL-17-induced inhibition of proteoglycan synthesis in cartilage by IL-4, 1300
regulation of synovial B cell survival in by VCAM-1, 1115
regulatory CD4+ T cell subset, reduced expression and RA severity, 617
remission/relapse, HAQ and, 234
retrotransposable L1 elements in synovial tissue, 2634
salivary cortisol levels in patients with recent onset, 465
screening for osteoporosis in postmenopausal women starting corticosteroid treatment, 1967
sentrin at sites of synovial invasion, 599
severity of in Portuguese patients, 470
sonography for detection of bone erosion in, 2762
stimulation of MMP-9 production by IL-17 in human monocyte/macrophages, 1134

Rheumatoid arthritis (RA) (cont'd)

- stress- and mitogen-activated protein kinase activation/localization/ regulation in, 2501
- sulfasalazine treatment of, 495, 1345, 1927
- synovial biopsy and tissue analysis, 2619
- synovial macrophage depletion with clodronate-containing liposomes, 1951
- synovial tissue as source of osteoclast differentiation factor, 250
- taurine chloramine inhibition of cytokine production by fibroblast-like synoviocytes in, 2169
- temporal expression of inflammatory cytokines and chemokines in rat adjuvant-induced arthritis, 1266
- TNF α blockade, reduction of chemokine levels and leukocyte traffic to joints by, 38
- TNF α and oncostatin M levels correlate with degradation markers of collagen and aggrecan in RA but not OA, 281
- TNF α and stem cell factor expression in, 164
- TNF α and TNFR in Japanese patients, 753
- TNF α -induced apoptosis of human synovial fibroblasts inhibited by gene therapy, 1094
- TNP-470/AGM-1470, arthritis suppression and protection from bone destruction with, 2056
- treatment options for patients with MTX-resistant RA, 2316
- Val68Ile polymorphism of neutrophil chemoattractant *LECT2* and in Japanese population, 1419
- RNA, viral, and histologic analysis of inflamed synovium in Ross River virus infection, 365
- RNP antibody detection, quantitative radioligand assays using de novo-synthesized recombinant autoantigens in connective tissue diseases, 689
- Rofecoxib
 - clinical trial in patients with knee and hip OA, 978
 - comparison with ibuprofen and placebo on gastroduodenal mucosa, 370
- Romanus spondylitis, 1186
- Ross River virus infection, viral RNA and histologic analysis of inflamed synovium in, 365

S

- Sacroiliitis, in AS, 2011
- Salivary glands
 - expression of MMP in primary SS, 2807
 - lymphomas in SS, 908
 - suppression of MMP-9 in SS by adding inhibitor of NF- κ B α cDNA, 1756
- Salmonella*, disease outcome in *Salmonella*-infected patients, modification by HLA-B27, 1527
- Sapporo criteria, validation of, 440
- SB 242235, disease-modifying activity in adjuvant arthritis, 175
- SCID mice, fibroblast-mediated cartilage degradation modulated by articular chondrocytes in RA, 2531
- Scintigraphy
 - gallium-56 in macrophagic myofasciitis, 1520
 - ¹²³I-antileukoproteinase, microscopic cartilage alterations in rat knee joint with antigen-induced arthritis, 298
 - and protein-losing gastroenteropathy in SLE, 1900
- Scleroderma. *See* Systemic sclerosis (SSc)
- Secretory response, antibody-mediated in NOD mice, 2297
- Selectin, correlation between increased NO production and markers of endothelial activation in SSc, 1085
- Sentrin, at sites of synovial invasion in RA, 599
- Sepsis, *Staphylococcus aureus*-induced, macrophages in, 2276
- Septic arthritis
 - chronic destructive oligoarthritis associated with *Propionibacterium acnes* in patient with acne vulgaris, 2843
 - IFN γ administration and severity of group B streptococcal arthritis in mice, 2678

Septic arthritis (cont'd)

- induced by CpG motifs in bacterial DNA, 356
- Serine/arginine splicing factors, small nucleolar RNP scleroderma autoantigens associated with during apoptosis, 1327
- Serum transferrin receptor, for detection of iron deficiency in RA patients with anemia, 1016
- Short-tau inversion recovery MRI (STIR MRI), for occult skin and subcutaneous abnormalities in juvenile dermatomyositis, 1866
- Shoulder pain, multiple myeloma presenting as, 2608 "Shrinking lung," association with anti-Ro/SSA antibody, 2612
- Siblings. *See also* Twins
 - JRA, concordant incidence of, 2611
 - JRA, HLA linkage demonstrated by allele sharing in affected sibling pairs, 2335
 - quantitative genetic contribution to RA, 30
 - radiographic hip OA in women, 2410
- Signal transduction
 - IL-8 expression stimulated by monosodium urate monohydrate and calcium pyrophosphate crystals in monocytic cells, 1145
 - intracellular calcium ion stores and signaling in T lymphocytes from patients with chronic inflammatory arthritis, 1257
- Sine scleroderma, 444, 2618
- Single-photon-emission computed tomography (SPECT), regional cerebral blood flow in fibromyalgia, 2823
- Sjögren's syndrome (SS)
 - after hepatitis B vaccination, 2139
 - antimuscarinic acetylcholine receptor antibody-mediated secretory dysfunction in NOD mice, 2297
 - autoantibodies against dympyle, 1516
 - expression of MMP in labial salivary glands in patients with primary SS, 2807
 - frequency of t(14;18) translocation in, 951
 - hepatitis C virus infection in patients with SS and non-Hodgkin's lymphoma, 1187
 - mannose-binding lectin gene polymorphisms and primary SS, 2851
 - muscarinic receptor autoantibodies, inhibitory effect on parasympathetic neurotransmission in, 1647
 - salivary gland lymphomas in, 908
 - suppression of MMP-9 by inhibitor of NF- κ B α cDNA, 1756
- Skin
 - involvement in SSc with diffuse scleroderma, 2437
 - MRI for occult skin and subcutaneous abnormalities in juvenile DM, 1866
 - skin thickness score as predictor of SSc outcome, 2445
 - stiff skin syndrome, 1542
 - vasculitis in an old tattoo, 1184
 - vinyl chloride causes fibrosis in microchimeric mice, 2598
- Small nucleolar RNPs, association with phosphorylated serine/arginine splicing factors during apoptosis, 1327
- Soluble complement receptor 1 (CD35), sCR1 in gene therapy of collagen-induced arthritis, 1698
- Soluble TNFR type I, for RA in rat models, 2648
- Sonography
 - of bone erosion in patients with RA, 2762
 - of tendons, 969
- Spanish population, GCA association with polymyalgia rheumatica, with different TNF microsatellite polymorphisms, 1749
- Spine
 - association of osteophytosis and TGF β 1 genotype, 452
 - bone mineral density of in male RA patients, 2776
 - cervical spine subluxations and combination DMARD therapy vs. single-DMARD therapy for RA, 2397
 - normal peak bone mass at lumbar spine and forearm in young adults with juvenile arthritis in remission, 1504
- Spondylarthropathy
 - evolution of chronic recurrent multifocal osteitis toward, over long term, 109

- Spondylarthropathy (*cont'd*)
 familiar form of, 1356, 2140
 gene factors predisposing to, 485
 HLA-B27 in, 724
 localization of disease in, 730
 T cells and enthesal ossification in DBA/1 mice, 844
- Spondylitis, Romanus, 1186
- Spontaneous arthritis
 in class I-deficient mice, 2290
 in KRN transgenic mouse, 2571
- SR proteins, as autoantigens in patients with SLE, 1768
- Staphylococcus aureus*-induced arthritis and sepsis, macrophages in, 2276
- Stem cell factor, TNF α and expression of in synovial fibroblasts, 164
- Stiff skin syndrome, 1542
- Streptococcal arthritis
 IFN γ administration and severity in mice, 2678
 suppression of by HCG, 2064
- Stress-activated protein kinases, and MAPK activation/localization/regulation in RA, 2501
- Subacute bacterial endocarditis, with positive cANCA and anti-proteinase 3 antibodies, 226
- Subchondral insufficiency fracture, in rapid destruction of hip joint, 2423
- Subglottic tracheal stenosis, in Wegener's granulomatosis, 1654
- Sulfasalazine
 ANCA seroconversion induced by, 2488
 antibody-positive vasculitis, prevalence in patients with high antityeloperoxidase antibody levels, 405
 combination DMARD therapy vs. single-DMARD therapy for RA, cervical spine subluxations and, 2397
 poor-prognosis early RA, treatment with MTX, cyclosporin A, and intraarticular corticosteroids compared with sulfasalazine alone, 1809
 slowed radiographic progression in RA after treatment with, 495, 1345
 TNF α expression in macrophages inhibited by inducing apoptosis, 1941
 triple therapy for patients with MTX-resistant RA, 2316
- Superoxides, ICAM-1 and $\beta 2$ integrins stimulate neutrophil superoxide production of, 2248
- Sympathetic nervous system, response to IL-6 and fibromyalgia diagnosis, 872
- Synovial fibroblasts. *See also* Fibroblast-like synoviocytes
 anti-IL-1 for inhibition of cartilage destruction, in vitro, 1719
 cartilage degradation and invasion, plasmin inhibition, 1710
 evidence for second CD6 ligand by synovial fibroblasts, 329
 MMP-3 production in, enhancement by calcium pentosan polysulfate, 812
 TNF α and stem cell factor expression in, 164
 TNF α -induced apoptosis of human synovial fibroblasts inhibited by, 1094
- Synovial fluid
 antigen-specific T cell response in reactive arthritis by flow cytometry, 2834
 bone morphogenetic protein receptors in RA joint, 2046
 intracellular calcium ion stores and signaling in T lymphocytes from patients with chronic inflammatory arthritis, 1257
 nuclear RelB in RA patients, 791
- Synovial tissue
 acidic fibroblast growth factor in synoviocytes, 2152
 anti-TNF α therapy retards synovial TNF synthesis, 2391
 antigen-presenting cells containing bacterial peptidoglycan in patients with RA, 2160
 bacterial DNA and bacterial peptidoglycans in joints of RA patients, 593, 1061
 bone morphogenetic protein receptors in RA joint, 2046
- Synovial tissue (*cont'd*)
 C/EBP β and C/EBP δ in rheumatoid synovium, 1591
 correction of abnormal RA synovial cell function by *jun* D transfection in vitro, 945
 EBV infection of and RA pathogenesis, 151, 1218, 2614
 expression of extracellular MMP inducer in rheumatoid synovium, 275
 human cartilage gp-39 and CD16+ monocytes in, correlation with joint destruction in RA, 1233
 macrophage depletion with clodronate-containing liposomes in RA, 1951
 macrophage-derived cytokine and NF- κ B p65 expression in patients with psoriatic arthritis, 1244
 markers of, molecular basis and clinical use of, 953
 nuclear RelB in RA patients, 791
 osteoclastogenesis from synoviocytes in RA, 259, 2523
 osteopontin messenger RNA and protein in synovium of RA, 1597
 retrotransposable L1 elements in RA, 2634
 sentrin at sites of synovial invasion in RA, 599
 as source of osteoclast differentiation factor in RA, 250
 stress- and mitogen-activated protein kinase activation/localization/regulation in RA, 2501
 synovial biopsy and tissue analysis in RA, 2619
 viral RNA and histologic analysis of inflamed synovium in Ross River virus infection, 365
- Synoviocytes
 acidic fibroblast growth factor in, 2152
 annexin I surface binding sites and regulation on fibroblast-like synoviocytes, 2437
 CD80-negative fibroblast-like synoviocytes and anergy in T lymphocytes, 1606
 Fas-mediated apoptosis, differential regulation of in rheumatoid synoviocytes by TNF α and basic fibroblast growth factor, 1106
 functional heterogeneity of, 2513
 regulation of synovial B cell survival in RA by VCAM-1, 1115
 stress- and mitogen-activated protein kinase activation/localization/regulation in RA, 2501
- Systemic arthritis, low-dose oral MTX in children with, 1849
- Systemic lupus erythematosus (SLE)
 accumulated T cell clonotypes in patients with SLE, 2712
 adoption by lupus patients who are infertile, 2380
 alternative medical therapies for, 1410
 anti-DNA IgG autoantibodies, genetics, induction, and molecular features of, 2132
 anti-double-stranded DNA antibodies, 2265
 anti-endothelial cell antibodies in normal and lupus pregnancy, 1511
 anti-IL-10 monoclonal antibody therapy in, 1790
 anti-protein S antibodies, prevalence in patients with, 557
 antidiotypic antibodies, cross-reactivity with DNA in, 429
 antinucleosome antibodies (IgG3 subclass) as markers of renal pathogenicity in, 76
 apolipoprotein(a) deposition in atherosclerotic coronary arteries of patient with, 2141, 2142
 association of damage in with corticosteroids, 1801
 autoantibodies to human nuclear lamin B1 in, 950, 951
 chylomicron metabolism in, 1033
 cytokine-producing T cells in, 711
 drug-induced lupus, chlorpromazine-induced lymphoblast apoptosis as causal factor, 1994
 Fas ligand gene mutation in, 135
 Fc γ receptor polymorphisms in, 2793
 genetics in Italian population and association with IL-10 gene, 120, 1442
 hepatitis B vaccination and exacerbation of, 468
 hepatitis C virus infection mimicking, 2801
 IL-10 blockade in, 1976
 intervals on chromosomes 1, 3, and 13 linked to in mice, 349

Systemic lupus erythematosus (SLE) (*cont'd*)

- juvenile-onset, nephrotic-range proteinuria as risk factor for early atherosclerosis in, 1405
 - LE cell phenomenon, antichromatin antibody specificity in LE cell-positive and -negative sera, 420
 - mannose-binding lectin deficiency and infections in patients with, 1657
 - neuropsychiatric, 48, 1903, 1904, 2045, 2428
 - nucleosomes as autoantigens in, 2307
 - ovulation induction and in vitro fertilization in patients with, 550, 2380
 - poly(ADP)-ribose polymerase and susceptibility, 1421, 1422
 - primary APS and SLE-related APS, increased sVCAM concentrations and severity of thrombosis in, 55
 - protein-losing gastroenteropathy in, scintigraphic diagnosis, 1900
 - restricted VH3 gene use of intravenous immunoglobulin-selected Fab, 2723
 - "shrinking lung," association with anti-Ro/SSA antibody, 2612
 - SR proteins as autoantigens in patients with SLE, 1768
 - susceptibility in populations of sub-Saharan African ancestry, 2378
 - TNF-308A and HLA-DR3 alleles, contribution of to susceptibility, 129
- ## Systemic sclerosis (SSc)
- α_2 -adrenergic constriction of isolated arterioles in diffuse SSc, 1886
 - abnormalities of erythrocyte membrane fluidity, lipid composition, and lipid peroxidation in, 894
 - anti-DNA topoisomerase I autoantibody response in, 2733
 - anti-fibrillin I antibodies in, 2464
 - antinucleosome antibodies as markers of renal pathogenicity in, 76
 - apoptosis and TGF β 1 in fibroblast selection and activation in, 2230
 - autoantibodies against dymple, 1516
 - autoantibody response to topoisomerase I in, 1074, 2733
 - correlation between increased NO production and markers of endothelial activation, 1085
 - dermal fibrosis in microchimeric mice caused by vinyl chloride, 2598
 - endostatin in, 889
 - endothelial cell apoptosis in, induced by antibody-dependent cell toxicity via CD95, 2550
 - Fas/Fas ligand and pulmonary fibrosis, 236
 - free radical-mediated injury in pathogenesis of, 894
 - HLA-DQA1*0501 associated with diffuse SSc in Caucasian men, 2005
 - increased IL-17 production in patients with, 2455
 - inhibition of geranylgeranyl transferase prenylation and inhibition of type I collagen gene expression in fibroblasts, 1624
 - microchimerism of, 1062
 - oral type I collagen tolerance induction, 1054
 - organ involvement in, 2437
 - polymorphisms of IL-8 and CXCR3 receptor genes in, 1633
 - sine scleroderma, 444, 2618
 - skin thickness score as predictor of outcome, 2445
 - small nucleolar RNP autoantigens associated with phosphorylated serine/arginine splicing factors during apoptosis, 1327
 - TGF β and PDGF genes in Native Americans with, 1068
 - transcription factor CBF in SSc fibroblasts, 2219
 - transcription factor Sp1 in SSc fibroblasts, 2240
- ## Systemic vasculitis
- adherent neutrophils and, 1337
 - epidemiology in UK, 414
- ## Systemic-onset JRA
- early predictors of poor functional outcome in, 2402
 - etanercept in children, development of diabetes mellitus during treatment, 2606

T

T cells

- accumulated T cell clonotypes in patients with SLE, 2712

T cells (*cont'd*)

- antigen-specific T cell response in reactive arthritis by flow cytometry, 2834
- autoreactivity to β 2-glycoprotein I in APS, 65
- bucillamine, transendothelial migration of T cells, 1616
- CD8+, CD57+ T cells from healthy elderly subjects suppress neutrophil development in vitro, 834
- CD80-negative fibroblast-like synoviocytes and anergy in T lymphocytes, 1606
- cytokine-producing, in SLE, 711
- enthesal ossification in DBA/1 mice, 844
- epitopes in reactive arthritis, 727
- intracellular calcium ion stores and signaling in T lymphocytes from patients with chronic inflammatory arthritis, 1257
- nucleosomes as autoantigens in SLE, 2307
- polarized T cells expressing CCR5 and CXCR3 in juvenile idiopathic arthritis, 765
- regulatory CD4+ T cell subset, correlation with Th1/Th2 balance and RA severity, 617
- Taurine chloramine, inhibition of cytokine production by fibroblast-like synoviocytes in RA, 2169
- Tempol, beneficial effects in rodent model of collagen-induced arthritis, 320
- Th1/Th2 balance, correlation with regulatory CD4+ T cell subset and RA severity, 617
- Th2-type cytokines, pulmonary fibrosis and, 236, 237
- Theophylline, reversal of antiinflammatory effects of MTX by, 656
- Thrombosis
 - in patients with connective tissue diseases treated with cyclooxygenase inhibitors, 1891
 - polymorphism of plasminogen activator inhibitor gene and, in APS, 2349
 - primary APS and SLE-related APS, increased sVCAM concentrations and severity of, 55
 - trophoblast gonadotropin secretion and invasiveness affected by antiphospholipid antibodies, 140
- Tissue inhibitor of metalloproteinases, MMP-3 enhancement by calcium pentosan polysulfate, 812
- Tissue engineering, engineered cartilage tissue, proton magnetic resonance microscopy, 1580
- TNFR-associated periodic syndrome, 1535
- Tobramycin, as novel therapy for adjuvant-induced arthritis and experimental autoimmune encephalomyelitis, 2583
- Tracheal stenosis, in Wegener's granulomatosis, 1654
- Transcription factors
 - C/EBP β and C/EBP δ in rheumatoid synovium, 1591
 - phosphorylation of transcription factor Sp1 in SSc fibroblasts, type I collagen gene expression and, 2240
 - transcription factor CBF in SSc fibroblasts, 2219
- Transferrin receptor ferritin index, for detection of iron deficiency in RA patients with anemia, 1016
- Transforming growth factor β (TGF β)
 - CILP/NTPPH and ePPi with aging, 2703
 - in fibroblast selection and activation in SSc, 2230
 - furin convertase in activation of for modulation of collagenase 3, 2100
 - in Native Americans with SSc, 1068
 - transglutaminase in activation of, in aging articular cartilage, 1729
- Transglutaminase, in activation of TGF β 1 in aging articular cartilage, 1729
- Trimethoprim/sulfamethoxazole, cost-effectiveness of prophylaxis against *Pneumocystis carinii* pneumonia in Wegener's granulomatosis with immunosuppressive therapy, 1841
- Trophoblast gonadotropin, in APS, 140
- Tuberculous arthritis, 709
- Tumor necrosis factor (TNF), association of GCA with polymyalgia rheumatica with different TNF microsatellite polymorphisms, 1749

Tumor necrosis factor α (TNF α)

- 5'-flanking region in Japanese patients with RA, 753
 - anti-TNF α therapy retards synovial TNF synthesis, 2391
 - correlation with degradation markers of collagen and aggrecan in RA but not OA, 281
 - expression in macrophages inhibited by apoptosis induced by sulfasalazine, 1941
 - Fas-mediated apoptosis, differential regulation of in rheumatoid synoviocytes by, 1106
 - induction of TNF α production by adhered human monocytes, 608
 - juvenile DM, TNF α -308A allele in, 2368
 - macrophages and induction of arthritis triggered by bacterial DNA containing CpG motifs, 2283
 - RA, association of TNF-region genetic markers with susceptibility to, 1366
 - reduction of chemokine levels and leukocyte traffic to joints by TNF α blockade in RA, 38
 - stem cell factor expression in synovial fibroblasts, 164
 - TNF-308A allele and susceptibility to SLE, 129
 - TNF α -induced apoptosis of human synovial fibroblasts inhibited by, 1094
 - TNF α -induced MMP-9 production by introduction of inhibitor of NF- κ B α cDNA, 1756
- ## Tumor necrosis factor receptor (TNFR)
- PEGylated soluble TNFR type I for RA, rat models, 2648
 - TNFR1 C30S mutation linked to autosomal dominant recurrent fever with localized myositis, 1535
 - TNFR-II in Japanese patients with RA, 753
- ## Twins. See also Siblings
- JRA, concordant incidence of, 2611
 - JRA, HLA linkage demonstrated by allele sharing in affected sibling pairs, 2335
 - quantitative genetic contribution to RA, 30
 - radiographic hip OA in women, 2410

U

- U1-70-kd antigen, autoantibody recognition of modified forms and clinical manifestations, 881
- UK, systemic vasculitis epidemiology in, 414
- Unmethylated oligo-DNA, collagen-induced arthritis aggravated by unmethylated oligo-DNA containing CpG motifs, mouse model, 2578
- Uric acid, aspirin mini-dose effect on renal function and handling of, in elderly, 103

V

- Vancomycin, for adjuvant-induced arthritis and experimental encephalomyelitis, 2583
- Varus malalignment, knee OA, obesity and, 568
- Varus-valgus alignment, association with patellofemoral OA, 1874

Vascular cell adhesion molecule (VCAM)

- correlation between increased NO production and markers of endothelial activation in SSc, 1085
 - inflammatory infiltrates in GCA, 184
 - mediation of monocyte chemotaxis in RA by, 1122
 - primary APS and SLE-related APS, increased sVCAM concentrations and severity of thrombosis in, 55
 - regulation of synovial B cell survival in RA by VCAM-1, 1115
 - Vascular endothelial growth factor, in polymyalgia rheumatica, 2472
- ## Vasculitis
- in an old tattoo, 1184
 - ANCA seroconversion induced by minocycline, sulfasalazine, or penicillamine, 2488
 - antibody-positive vasculitis, prevalence in patients with high antimitochondrial antibody levels, 405
 - Chlamydia pneumoniae* in giant cell vasculitis and correlation with topographic arrangement of dendritic cells, 1543
 - epidemiology of systemic vasculitis in UK, 414
- ## Very late activation antigen 4
- inflammatory infiltrates in GCA, 184
 - mediation of monocyte chemotaxis in RA by soluble VCAM-1, 1122
- ## Vinyl chloride, dermal fibrosis in microchimeric mice caused by, 2598
- ## Virus persistence. See also individual viruses
- chronic seropositive polyarthritis and hepatitis B virus-induced chronic liver disease, 232
 - viral RNA and histologic analysis of inflamed synovium in Ross River virus infection, 365
- ## Vitamin D, in corticosteroid-induced osteoporosis, 1188, 1189

W

Wegener's granulomatosis

- cost-effectiveness of prophylaxis against *Pneumocystis carinii* pneumonia in patients undergoing immunosuppressive therapy, 1841
- cyclophosphamide for, 1021, 2379, 2853, 2854
- cystitis, bladder cancer, and myelodysplasia in cyclophosphamide patients, 2854, 2855
- epidemiology of in Norway, 2481
- high-resolution CT in pulmonary disease in, 698
- interdisciplinary approach to patient care, 1021, 2379
- MTX and glucocorticoids in patients with glomerulonephritis, 1836
- orbital granuloma and subglottic tracheal stenosis in, 1654
- prediction of relapses by measurement of ANCA levels, 2025
- presenting as Pancoast tumor, 467

Y

- Yersinia*-induced reactive arthritis, antigen-specific T cell response in by flow cytometry, 2834